Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

Cereno Scientific, Capital Markets Day, 2024

By Inderes10/17/2024, 11:30 AM
Cereno Scientific

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Sten Sörensen
00:01 - 11:36

Hello everyone. I'm Stan Sorensen, the CEO of Sereno Scientific. We are a biotech based in Sweden. We are pioneering efforts in diseases with high unmet need, where we believe our research can deliver substantial value to patients. So I'd like to extend a warm welcome to those of you here in this location and to those of you following us online today. So it's been a year, a little more since we had the Capital Markets Day. And we've been looking forward to this a lot. And I think we have a very exciting setup of speakers. Both are internal experts as well as others who have joined us today. So first, some house rules for those of you here in case of an emergency. There's one exit, and we have a very tight agenda. There is one break in our three hours that we'll spend together. So you can decide whether you want to drink coffee or do something else. Powder your nose. But you're going to go upstairs, and I suggest you bring the coffee down so you have a chance to not miss anything that we are saying here. There's going to be a Q&A. So there are questions that you can ask at the end, about 20 minutes if I remember correctly. And there have also been questions sent to us via email. So we'll try to answer those in a panel up here. And after the scientific and business session, we will gather together in the foyer and chat a little about what we have experienced here today. So let's get started. So the setup here is we have a doctor, Raymond Benson, our principal investigator based in New York at Mount Sinai. And we have Doctor Jason Guichard from South Carolina. He is the doctor who has recruited the most patients in our pH trial. He will also be joining us here for a few minutes. And of course, many of you know Professor Michael Holland from the University of Michigan. He's sitting in the front row here. He will present one piece of the agenda for you that we believe is very exciting too. And you have seen the recent communication that we have done a partnership agreement with Florida. So the CEO and one of the founders of Florida will also join us here today to discuss that technology and how it can be helpful for our efforts to develop valuable drugs. So this is the agenda. I won't go through it now. And I think you probably have it with you. We'll return to this agenda as we go forward. First, I'll start with an introduction about what we're trying to do at Serano. And it's about this. So, this is a person. Healthy midlife, no diagnosis. Suddenly, this happens. She is diagnosed with pulmonary arterial hypertension. And this is actually what's happening. She has a progressive remodeling of her pulmonary arteries, resulting in very narrow, very stiff arteries with high pressure. Eventually, the right heart fails and she dies. Current treatments don't address this. Life expectancy is seven years. Midlife. This person probably has a family. Children. So the question you should ask yourself if you are in the business of innovation is, what if? What if we could develop a drug that's disease-modifying? It's another example: a healthy couple. One of them is suddenly diagnosed with IPF, another rare disease. Even shorter life expectancy. Fibrosis of the lung. No drugs on the market address the underlying disease. What if somebody could develop a drug that could halt, or maybe even reverse this progression and enhance life, enhance quality of life? A third example: the most common cause of death on this planet is thrombosis, resulting in the most dangerous conditions, such as thrombosis of the brain, known as stroke, or myocardial infarction. 20 million people a year die of this issue. You'd like to have more effective drugs, but you can't because all the drugs out there cause very dangerous bleedings. Three out of 100 die; 25 out of 100 experience bleedings, as seen in this picture. Get bleedings like you see in this picture. You have to go to the hospital in many cases. So what if you could develop a drug that doesn’t cause bleeding, could be added to other drugs, and would result in higher efficacy without increased risk? So what we are trying to do at Serrano is develop drugs that answer the question or meet the demands of these needs, enhance life, and prolong life. Root cause of the disease. Disease-modifying agents. Now we believe we are pioneering the effort with STAT inhibition. So, epigenetic modulation through HDAC inhibition. And we're bringing that into cardiovascular disease. And now also lung disease. The reason is the multitude of publications and studies done; more than 500 articles have been published, and 100 of those were published in The Lancet by our Scientific Advisory Board in 2021. The recent Nobel Prize is also related to epigenetics, by the way. Okay. MRI. In our portfolio, we have two inhibitor drug development programs. And one of those we just finished the Phase 2 program in the rare disease pulmonary arterial hypertension. And we'll revert to all of these three programs throughout the day. And today, we announced that the target indications of CSO 14 are novel. Hdac inhibitor is going to target IPF, interstitial pulmonary fibrosis. It's currently in phase one and will complete phase one by the summer next year, then we'll move it into phase two. So it's pretty close, right? Two programs are currently focused on rare diseases. The third program, CS 585, has been documented to prevent thrombosis without increasing bleeding risk. We'll discuss today and my comments will entice you with some new information. Now, why do we do this? We do it for the patients. We'd like to develop these drugs to help the patients. Higher quality of life. Longer life. But of course, the way to the market, to the patient, can go different ways. About 70% of all new drugs are developed by biotechs, but pharma brings them to the market. The industry involves the big players. So that's why you have all these deals between pharmaceutical companies and biotechs. So we are developing this to be valuable for patients, but of course, also to be attractive for such deals. And if you look at our portfolio, you can see the rare disease pulmonary arterial hypertension CS1 and IPF program now identified for CSO 14. So we have an attractive portfolio. We have a thrombosis portfolio. Both CS1, actually CSO 14, and CS 585 can prevent thrombosis without increasing bleeding risk, as documented in very translatable models in mice. By my calculations, right here. Very translatable to humans, I should say. So. We are based in Gothenburg. We were founded in 2012 and entered the stock market in 2016, since then we have grown the company. I'll revert to that a little later today, but you are part of the almost 10,000 shareholders that Soriano has as shareholders today supporting our efforts, and we're very thankful for that. We just moved out of Astros Bio Venture Hub into Goco, a very vibrant research hub next to AstraZeneca in Gothenburg in Rosendahl, where they're a little more grown up. Companies from startups are moving, so we moved there in July and it's a good place to be. That's where the management of what we do have offices. But look here, these are all the various companies, consultants, etc. , that we work with collaborators worldwide. And the recent addition here is Fluida. You can see that on the top, which you will hear more about. today. We have ongoing collaboration with Abbott. We have four years plus four years of collaboration with the University of Michigan and so many, many collaborations and continuous work with these parties. So, we're not doing it alone. And we also have a very strong scientific advisory board supporting our efforts. And you will hear from one of them today, Doctor Raymond Benza. And I'd like to introduce him now. Actually, I hope the technology works. Yeah. Hello, doctor. Hello.

Dr. Benza
11:37 - 11:37

Good morning.

Sten Sörensen
11:37 - 11:39

How are you?

Dr. Benza
11:39 - 11:46

Very well. You have an empty office. I'm in transit. Okay.

Sten Sörensen
11:46 - 12:06

All right. All right. You're very welcome. So, you know, as you know, we have an audience here of about 60 people, mostly shareholders in the company. And then we're also broadcasting live over the internet. So that's your audience. And I know you're going to speak about pulmonary arterial hypertension. Thank you.

Dr. Benza
12:06 - 29:03

It's my pleasure. And I am curious if the videographer could focus on the screen at this point, because that way I can see how my slides are being advanced. Perfect. And if we can move to my first slide, it's a real pleasure to be here this morning to speak for Sereno regarding therapeutics and pulmonary hypertension. And the focus of our small conversation today really will be to discuss what I feel are the missing links in contemporary drug therapy. So Sten mentioned that I am a professor of medicine and the system director for pulmonary vascular diseases at the Mount Sinai Heart Institute at the Icahn School of Medicine here in New York City in the United States. If you move to the next slide. So today we'll talk a little bit about the missing links in contemporary drug therapy. As most of you know, in the audience, pulmonary hypertension is a deadly disease without cure that primarily affects middle-aged women in the prime of their lives. And we've done a lot to improve mortality with this disease. But our seven-year mortality rate is still very excessive, and our patients continue to experience numerous morbid events. And we believe that much of this is related to a variety of reasons outlined here. But one of the most important reasons, as the last one is that many of the drugs that we have to treat pulmonary arterial hypertension do not target the disease itself. And we're going to delve into that throughout this talk. But this will be the main focus of what we'll discuss today. If you could advance the slide. So the way we predict prognosis in pulmonary hypertension is by using multidimensional strategies. And this is important because we know that no singular variable like NYHA class or natriuretic peptide levels really gives us the full description of how a patient progresses with this disease. Advance, please. And our current treatment strategy, our goal is to achieve a low risk status. If you could advance one slide, please. It's the treatment of a low-risk status defined as less than 5% mortality at one year. So we use these multi-dimensional strategies to try to push patients in this direction. Next slide. Now the reason this is important, as I mentioned earlier, is if you hang your hat on a singular feature like NYHA class or the six-minute walk distance or even hemodynamics, you can see that if you use these variables in and of themselves, their likelihood of telling you the wrong information is very high. And that's why we use multi-modality prognostic equations like the Reveal Score, because it gives us a significantly greater enhancement in our ability to predict who will or will not have an event and what the effect of our therapies are on a patient's timeline, course, and progression through this disease. Next slide, please. The systems that we use now, if you can just advance the animation one so we can see the scoring systems. The systems that we currently use from this multi-dimensional strategy are called the Reveal Score, and this is a score that I helped develop a number of years ago. It uses a variety of demographic factors, as well as factors from diagnostic studies, to paint the entire picture of how a patient will progress through this disease. And these scoring systems, which are used as continuous scores, allow us to get multiple lines of risk. If you can advance the slide so that we can depict a patient's prognosis in a very linear and very granular fashion. So improvements in score mean improvements in outcome, and detriments in score mean worsening outcomes. If you could advance one slide, please. So the advantages of using scoring systems that have this continuous risk is that you can follow the integer of change very granularly if you can move to the next slide. So if you're using the Reveal score or the Reveal Lite score, it is very important to understand that if you have a one-point decrease in score at 12 weeks, that patient is predicted to have a 62% decrease in the relative risk of clinical worsening. And no matter which trial we have profiled this in, we see results from the Freedom EV trial, from the Gryphon trial, and from the Patent trial; this very granular change in score always reflects an improvement in outcomes. This is very, very important. This is one of the reasons why we use this scoring system in the phase two trial, because it gives us this very good estimation of how patients will improve if they can improve their score in this manner. Next slide. So, let's talk a little bit more about what we have and what we don't have in terms of contemporary drug therapy. And we'll talk a little bit about how survival and morbidity in this disease are still too high, how our current disease-targeted therapy really focuses on vasodilation, as opposed to truly remodeling the blood vessels, how our current drugs lack specific tissue targeting, what the side effects of our current profiles are, and why there's a persistent need for parenteral therapy to really move our patients in the forward direction, and why we need new drug development in this area. Next slide. So, our event-free survival and quality of life in pulmonary hypertension. Is this really where we want to be with our current contemporary therapy? Next slide. As I mentioned earlier, pulmonary hypertension remains a very deadly disease despite all the drugs we have in our current armamentarium. Our seven-year survival rate, although improved from what it was in the past. In fact, we've tripled life expectancy. But a seven-year mortality rate in a disease that primarily affects middle-aged people is really not acceptable. Next animation. And so, there's still too much death and suffering, even with contemporary drugs that we have to treat this disease. Next slide. In addition to still having an unacceptable mortality rate despite our improvement in survival, our patients continue to experience morbid events that have remained unchanged over the last two decades of drug development. Our patients are still being hospitalized for worsening pulmonary hypertension and right heart failure, and our patients are still requiring escalation to triple therapy, including parenteral prostacyclins, in order to maintain stability. Next slide. In fact, as you can see on this slide, if we don't throw everything at our patients and use triple combination therapy upfront. Greater than 50% of our patients will still remain at high risk. And this is very, very significant because we want to drive people to this low risk. We want them to have the lowest Reveal score possible, because that's how we know that they're going to have an improved survival. Next slide. So our mortality still remains very unacceptable even on the best and most aggressive contemporary therapy. And this slide shows you that our upfront mortality, even with triple combination therapy at three years, is very significant and unchanged, even when using other additional therapies. So we really need more and diverse therapeutics beyond what we currently have to significantly reduce mortality. Next slide. So if you look at our current medications for the treatment of pulmonary arterial hypertension, and you approach this from a meta-analysis perspective. And you look at mortality and clinical worsening hospitalizations. You see some very interesting things. If you can advance the animation, you can see that all of these really hit the unity line. Next animation and then the subsequent animation. So as you can see here, all of our contemporary therapies really hit the unity line in terms of mortality, clinical worsening hospitalizations. And this is why we really need the advent of new therapies that focus on the disease and the remodeling of the blood vessels, beyond just vasodilation. Next slide. So obviously, what's very important to our patients, as opposed to living longer and staying out of the hospital, is whether they really have an improvement in the quality of life. Uh, advance please. And you can see that despite what I've shown you, the quality of life on our current therapeutics still remains very poor. And again, if you look at the hazard ratios and the forest plots of these, you again see some of the similar things that we saw for hospitalizations, mortality, and morbidity; that is, our quality of life with current medications has really not improved very much. Next slide. If you look further at this meta-analysis, you see a lot of brown, orange, and yellow on this slide. And in this meta-analysis, those colors represent no improvements in our major endpoints that we want, including functional outcomes, hemodynamic improvements, safety outcomes, and efficacy outcomes. So we have a lot more work to do despite what we have in our contemporary armamentarium to really push these functional, hemodynamic, and outcome measures forward. Next slide. So, what do our current drugs do? How do they really change the pathology of the disease? Next slide. Most of our therapeutic agents work on both the endothelial cells and the intrinsic smooth muscle cells. And their major activity is really to stimulate the smooth muscle cells to relax and cause the blood vessels to dilate. But we know that this vasodilation method really isn't pushing our patients where we need to be. As I mentioned earlier, please advance the animation; this is where we see an explosion in new research. We are looking at a variety of different pathways that can truly change the integrity of the blood vessels, as opposed to merely causing them to dilate. Next slide. And again, just to push the point home, if you look at it, are we really remodeling the pulmonary vascular bed with current therapeutics. You can see something very interesting here. So if you look at mean pulmonary artery pressure. Pulmonary vascular resistance shows that using either single or dual therapy hardly changes these hemodynamic parameters, which define this disease. Animation, please. It really depends on use. It really depends on using our full armamentarium, including parenteral prostacyclins, where we really see the dramatic reduction in pressures and resistance that we want, which we know mitigates this disease. Next slide. So our current drugs obviously are not tissue targeted and that's what we want. Next slide. We can also see that we continue to have terrible side effects with our contemporary medicines. That's compounded by multiple drug use. If you can advance the slide, 47% of our patients experience significant adverse events from their medications. Advance the slide. And these adverse events occur with significance and lead to significant medical non-adherence if you could advance the slide. So despite having these medications, the side effects really prohibit us from using them to their fullest extent. And this is significant. So, we have drugs that don't remodel the blood vessels and, because of side effects, are very difficult to use and to maintain good adherence to. Next slide. And this is where again new medicines are needed involving all these pathways including mitigating dysregulated angiogenesis, working on the extracellular matrix, working on calcium signaling, and enhancing BMP-2 signaling, mediating and mitigating other growth factors, and invasive active mediators, in order to really drive this disease and to make these blood vessels move in a direction where they're not only vasodilated, but where the intima and media of the blood vessel have regressed and the vessel becomes a larger lumen size because of remodeling, not just vasodilation. And we currently have clinical trials targeting metabolic syndromes, glycolysis, and fatty acid oxidation. Next animation. We have new drugs that target inflammation in pulmonary arterial hypertension by modulating cytokines and inflammation. Next animation. We have new drugs that are modulating the estrogen pathway, the transforming growth factor (TGF) pathway that are augmenting BMP signaling and working on oxygenation. Next slide. But even with these new trials, we can see that many of them have failed to meet their clinical endpoints or have remained neutral, including some very recent trials using inhaled Minitab and modulating the serotonin pathway did not meet their primary endpoints. Next slide. So the conclusion from what I just told you is that despite our contemporary therapy, mortality has improved but remains suboptimal. Our morbidity remains substantial. We have really suboptimal improvements in patient well-being and functional capacity, and the traditional pathways have limited efficacy. Now, it only affects a small subset of the available pathways to develop downstream therapeutics. The side effects are prominent, leading to suboptimal drug compliance. And tissue targeting is limiting. And this is what really compels us to develop new targeting paradigms to effectively mitigate this disease. Next slide. And this is where we feel CS1 comes in because of its unique properties. Its anti-fibrotic and remodeling activity, related to this, its anti-inflammatory activities, which I showed you, is a very prominent mechanism driving this disease. Its known reduction in pulmonary pressure in preclinical models and very specifically, its antithrombotic activity. One of the main pathophysiologic mechanisms that drives this disease is microthrombosis. And so, this antithrombotic activity through HDAC inhibition is a very important mechanism that drives this process in the right direction. Next slide. And you'll hear a lot about the phase two trial that we just conducted, led by Sten and some of the other speakers. But nonetheless, I think it's important to highlight what we did in this particular study. Next slide. We really wanted to take advantage of the novel. This novel compound with its novel action, particularly its inhibition. We use novel innovative endpoints in this trial, including the Reveal tool, which I mentioned earlier. A change in score reflects an improvement in morbidity and mortality. We used cardiac MRI to really carefully evaluate changes in the right ventricle. We used the CardioMEMS device instead of standard hemodynamics because of its enhanced ability to detect changes over periods of time. As many of you know, in standard hemodynamics, these measurements can change throughout the day. And these hemodynamics that you classically see are really only small snapshots in time. So, being able to understand the area under the curve and the changes in these pressures is ultimately very, very important. Changes in the total time that we see a patient experiences with reduced pressure really translate into improved outcomes. We're looking at novel biomarkers in this study, as well as the traditional endpoints of six-minute walk test, standard hemodynamics, echocardiography, and biomarkers. So with this, I hope I have properly informed you to let you know that we need new pathways to explore as our current medicines are really not doing what we want for this deadly disease, and new compounds with novel actions like CS1 will hopefully drive us in this direction. And with that, I thank you for your attention.

Sten Sörensen
29:03 - 29:29

Thank you, Dr. Benza, for an excellent and informative presentation. So I know that we might have space for a couple of questions from the audience. If anybody is brave enough to ask. Any questions? Here's one here. Hi.

Joe Hedden
29:29 - 29:31

So, thank you.

Sten Sörensen
29:31 - 29:32

Maybe say your name.

Joe Hedden
29:33 - 30:03

Yeah. Joe Haden. Ah. Securities. Um, just in terms of the adverse event profile of the current combination therapy approaches. I mean, how do you see that evolving as hopefully disease-modifying therapies like CS1 come in? I mean, these drugs are being added on top of what are presumably combination therapies. So, is there any way that this is going to alleviate the current side effect profile of the drugs? Or is it just that so many patients don't go on to pulmonary prostacyclin?

Dr. Benza
30:04 - 30:43

That's an excellent question. And what we're hoping with these new drugs that have very potent vasoremodeling characteristics is that we'll be able to wean patients off some of their standard vasodilators. So the way I see that management will evolve in this disease state is that we will stabilize patients using our contemporary medications. We will start our vasoremodeling agents. And when these agents start remodeling, the blood vessels will be able to peel back some of these vasodilators. So patients will experience far fewer side effects from them, because we have the advantage of remodeling that we're doing with these newer therapeutics.

Joe Hedden
30:45 - 30:45

Thanks.

Sten Sörensen
30:47 - 31:00

Any other questions? All right. Thanks a lot, Ray. And I know you need to get back to the clinic, I guess. So, talk to you soon.

Dr. Benza
31:00 - 31:06

Thank you so much. And if anyone has any further questions for me, please email me. I'd be happy to answer them.

Sten Sörensen
31:06 - 31:30

Excellent. Thank you. Okay, so we are on time. I hope you found that useful and informative. And now I'd like to invite our head of R&D and Chief Medical Officer, Doctor Rahul Agarwal. Thank you very much.

Dr. Rahul Agrawal
31:30 - 55:57

Stan, and it's a delight to be here. And I welcome you also to this day. And as you could hear already from Ray, there are several unmet medical needs, even though there are many, many medications on the market. But there's still a high unmet medical need. You also heard from him that there are certain areas that need to be addressed when we look at specific endpoints. He mentioned the REVEAL risk score. He referred to the functional class. I'll go into more detail there and try to elaborate on why we did what we did, what we saw, and then maybe share those results with you. So this is me. You see a much younger picture of mine than now, the original. But please don't be surprised. They're photoshopping; it does it all. So, I think you had briefly seen the slide from Stan. These are the three compounds that we have. They're progressing well. We're going to talk about our lead compound and the phase 2a trial that we performed. CS1, as you heard, is already in phase one, and CS5 is also advancing. You're going to hear some more very exciting news from Professor Hollenstedt and Bjoern, our Chief Scientific Officer as well. So allow me to just briefly go into a little bit of introduction, and maybe it's a repetition of what Raymond Benza was showing you, but I would like to hone in on that; it means focus on the reverse remodeling. What does that really mean? If you look at the vessels on the left-hand side, you see a healthy vessel, a very dilated vessel with good blood flow over time. Reverse remodeling, though it may have a positive connotation, is actually something very deleterious and dangerous because the vessels undergo vasoconstriction and become tighter and tighter. That means the blood flow. But with that, the oxygenation of the tissues behind it is not as optimal. So this is something which one would definitely like to reverse. There are several factors which have been identified over the years that lead to this reverse remodeling, such as endothelial dysfunction and inflammation. That means there are these fibrotic changes in the vessel walls, including plexiform lesions. We're going to show you also what kind of effects we have with some very new data that has just come out. And of course, all in all, you see vasoconstriction, which means tightening of the vessels. And naturally, that means there is an increased strain on the heart, especially on the right side of the heart. This is what people often die from: shortness of breath and right heart failure. So these are the things that one has to really address. So far. The current therapies are primarily vasodilators. That means for a short time they cause the drugs to dilate, but they do not address the underlying cause. So there are key unmet medical needs. You heard that also from Doctor Menza: their unmet medical needs and the missing disease-modifying aspects. And of course, this is very important for patients as well. They should be safe and well tolerated because if a drug is not well tolerated, it will not be used. As you also saw, nearly 50% don't take their drugs because they don't tolerate them. So something one should keep in mind. So what we believe, and what we are addressing, is that we're tackling. If you'd like, the root cause of this reverse remodeling. And what we want to show is that we can hopefully come from sort of the late stage of pulmonary arterial hypertension and reverse it to some extent. Why? Because, as you saw in one of the previous slides from Stein, we demonstrate anti-fibrotic and anti-inflammatory properties which we have observed. And I'll show you some pulmonary pressure reduction, among other things. There is significant promise. And that's one of the reasons why, although we performed this trial, this promise also stems from and has been demonstrated in preclinical trials. I just want to show you two of those which were performed with VPA in standard animal models, including rat models with so-called monocrystalline rat models, the hypoxia model, and also other further models. And what you see there is that if you give VPA, there is a reduction of the wall thickness on the left-hand side, those bars that you see, and we have highlighted that with the blue arrows. And on the right hand side, what you see is there is a certain reduction of the pressure, but also of the so-called muscularization of the vessels. That means vessel thickness. So if you give VPA, there is an improvement. These preclinical trials are of course very promising, but so far there have been no clinical trials in this direction dedicated to PA patients. So this is what we have done. Basically, the goal in an ideal sense would be to, of course, reverse pathological remodeling. But you also heard from Doctor Benza that this is a deleterious, continuously worsening disease with no spontaneous improvement. So of course, we would love to see reverse remodeling. But even if we could stop the progression, that is a big win in itself. Please keep that in mind. Not only stopping reverse regression, but if we can stop the progression, that would be very beneficial. That means if the patients are either stable or improve, that is the best we can hope for a medication or a treatment in this case. So I'll just briefly go into what the results of our phase two A trial were. You may have heard it at the webinar, but we'll go a little more into details here. Again, it's a phase two, a prospective, randomized, multicenter trial. And a very important primary endpoint was safety and tolerability. And we explored efficacy parameters. Keep that in mind. All right. I'd just like to briefly highlight, and I'll go into all the aspects one by one in more detail. The primary endpoint and this is a big success. Primary endpoint of safety and tolerability was reached. Keeping in mind what Doctor Benzo said, for other drugs, many are not tolerable, so we have a good and safe drug. Very important prerequisite. We also looked at exploratory efficacy parameters, and I'm going to go into detail regarding the revealed risk score. We'll tell you why we chose that. The functional class. I'll tell you exactly what the importance of that is. And also some results of the CardioMEMS, the continuous mean pulmonary artery pressure measurements. Okay. And then all in all, the nice thing is we’d like to show you how that is consistent and how we think this is sufficient to take the next steps for another larger trial. You may recall what the study design looked like. All in all, the primary endpoint, as I was saying, was safety and tolerability. We had used CardioMEMS from Abbott in close collaboration with them. They were also excited to collaborate with us in this patient group. We had a treatment period of 12 weeks. We had three dosages: 480, 960, and 1920. In the end, we pooled the data together. Why? We'll show that to you later. But what we saw is that all of them, if you look at the blood levels, were practically the same, allowing us to group them together. This you will also see when we show the results; it will be a grouped result of all the patients. All in all, we had 25 patients in the safety analyses, and of those, 21 in the efficacy analyses. And I'll go into the details one by one, their 12-week treatment. And all in all, this was the thing. So after 25 patients, our clinical steering committee advised us to stop the trial because they said we had gained sufficient insights, so there was no need to continue, keeping in mind the primary endpoint was safety and efficacy. All in all, we had screened 38 patients. Of those, 25 were initially randomized with a very nice distribution across the three dosages: nine, eight, and eight. And as you can see, four were early terminated, three of whom were because one withdrew consent, one had a sepsis unrelated to the drug, and one sort of had adverse events. However, we don't know exactly the reason as these are multimorbid patients taking many medications, and it was not specified whether it was CCDH1 or something else. And the fourth one we had to exclude because of protocol deviation, since that patient was taking drugs which were not allowed in the trial. So, out of the 25, we have 21 patients in the efficacy analyses. All in all, as you know, three fourths of the patients were females. Unfortunately, this is a predominantly female-affecting disease. Most of the patients had idiopathic pulmonary arterial hypertension. Please keep in mind that in this trial, every single patient was already on standard of care for at least three months. Stable standard of care. What does that mean? They were getting between 2 and 3 drugs, which are approved and seen as first-line either endothelin receptor agonist or PDE5 inhibitor or prostacyclin. And our drug was administered in addition to the standard care. Yeah. The functional classes were two and three. 40% were in function class two and 60% in function class three. So, I think you have heard it—I love to repeat it. So we reached the primary endpoint of safety and efficacy. All in all, there were no serious treatment drug-related events. It's very important to note that this could have led to stopping the trial. Of course, there were adverse events, which is obvious. There were nausea and the usual well-known side effects, but there were no serious drug-related adverse events. And we have highlighted that in gray. All in all, good safety and tolerability. And we also, of course, looked at the liver values because, as you know, there are reported liver enzyme increases. We did not observe any CS1-related liver enzyme increases, nor did we see any clinically relevant decreases in platelets or incidents of bleeding. So again, a very good sign. All in all. And of course, with that, CS one was well tolerated in these 25 patients. So this was the primary endpoint of safety and efficacy. Then, of course, we wanted to also examine the efficacy parameters. But these are exploratory. Why are we really pointing that out. Very simple. It's a small 25-patient trial. Efficacy parameters, as you also heard from Doctor Benza, show huge variability. And of course, you need much larger trials. But our aim was to harvest signals to see if our drug is doing any good. Already in the first 12 weeks or not. So that's why these are exploratory efficacy parameters. Despite that fact, we see compelling positive signs regarding the revealed risk score. And I'll go into all three of them in detail now. Reveal risk score, functional class, and the CardioMEMS data, I'll call it. That means a continuous measurement of pulmonary artery pressure. So, mean pulmonary artery pressure. All right. Okay. So let me start with the Reveal risk score. You have seen that Dr. Benza just showed that. What it shows is that the higher the score, the higher the mortality rate. And this score is composed of several components, nearly a dozen. It's like a composite endpoint, if you will. It includes a W.H.O. class. It includes a WHO class. It includes gender. It includes age. It includes functional class. It includes six-minute walk tests. It includes a lot of hemodynamics. It includes echocardiogram data. So a lot of things are put together. And the revealed risk score has been identified as the most powerful prognostic risk score. Of the various risk scores that are available. And it's very important, if you can reduce the risk score by one within 12 weeks, that translates. And you heard that also from Dr. Benza. It translates into a 23% reduction in mortality within one year. That's remarkable. Just imagine, in 12 weeks of treatment, you reduce the risk score by one point. That means a 23% reduction in mortality within one year. Taking into account that patients only have a mean survival of seven years. They're in the middle of their ages. They're around 50, ladies in the middle of their lives, with a family and jobs. And you can just improve mortality considerably by improving the revealed risk score. Keep that in mind. How is our result? We showed improvement in 43% of the patients. So, nine out of 21 patients showed an improvement of one point after just 12 weeks. In this trial, we showed improvement in 43% of the cases. So nine out of 21 improved by one point. And if you recall what I had shown you in the other slide, the goal has to be either. Of course, reversal is the ideal outcome, but stabilization is also significant. So we looked at that. So, all in all, 15 out of 21, that is a 70%, had either improved or stabilized their revealed risk score. That is remarkable. This already within 12 weeks. And keep in mind, and I'd like to repeat, that a one-point reduction within 12 weeks translates into a 23% reduction in mortality within 12 months. Just think about that. 12 months is one year, October 2025. If you can reduce the mortality rate by 23% by improving the risk score, that is indeed remarkable. I just want to bring some life to the numbers. Numbers are numbers, but when you think about it, this is something impressive. So, this is the REVEAL risk score, the composite endpoint. This is one aspect we examined because for a small, initial exploratory trial, it is particularly valuable. But we looked at further things. The physician doesn't have all these tools. It doesn't have a right heart catheter to push every time. It's an invasive thing. So what they usually rely on is, of course, their impressions. And that is functional class. You may know what functional class is all about. Functional class is very simple. Divide into four classes. Four is sort of already in bed at rest. They have complaints. Functional class one is at rest. No complaints. Two and three are in the middle; two is mild complaints when at rest, and three is marked complaints at rest. Why is that important to know? Because this is something which the physician, whether she or he, takes as a decision point to change, alter, improve, or extend the therapy if need be for a patient. So, functional class influences everyday decisions. And I'm saying this myself as a cardiologist; it is very important because you base your decisions usually on how you perceive the patient. And that's why we, of course, wanted to see what that looks like. As you can see here, we had in one third of the patients, seven out of 21, an improvement in functional class already within 12 weeks, and 18 out of 21 either improved or were stable. To give you more details, most of the patients were in functional class three but improved to functional class two, and there were some who improved from functional class two to one. Keeping in mind what I said before, what that means at rest. No complaints if you're in functional class one; mild complaints in class two. So, every improvement is actually a big deal. And stabilization or improvement is, in itself, something very remarkable. So all in all, 86% were either stable or improved within these 12 weeks. Let's have a look at another parameter, hemodynamic. As you know, right? A right heart catheter is an invasive tool. You cannot do it every day. I performed thousands of these procedures during my career while I was in the clinic. But you don't do that every day. So for a trial, you do it usually once at the beginning and once at the end. So you just have two time points. That's it. And you try to derive your conclusions from these two values. If the patient improved, didn't improve, or whatever. So what we tried to do is to get a better feel for it and used CardioMEMS. Cardiomems enables continuous monitoring. It allows for the continuous measurement of the mean pulmonary artery pressure, which is then recorded. The means are extracted. Explain that. But what happens is, at the first right heart catheterization, you implant a tiny device into the pulmonary arteries. And then what happens is that it is fixed there. And what the patient has to do is they get a mat at home. They just have to lie down there. And for 20 seconds, those 20 beats, or whatever the heart rate is, are averaged and measured. And then that is done over the extent of the trial; in our case, it was 12 weeks. So all in all, it was around 85 days. So what was the result. So the result was that. Most of the patients had a reduction in their mean pulmonary artery pressure (MPAP). That means mean pulmonary artery pressure in CardioMEMS. As you can see on the y-axis, this is MPAP. Area under the curve, AUC. And we also provided the units for 1 to 85 days. And as you can see, we have highlighted this special patient; the patient's case is shown in bright green. And for others, there were some that even had a larger improvement in their area under the curve. If you want to translate this to right heart catheters because you say, well, I just know values of two, three, five. Suddenly I see 400 mm of mercury. What does that mean? Rule of thumb. Very simple. If you just look at it, these values are between 200 and 400. If you just divide them by 85, you get values around two and a half to five millimeters of mercury. That is approximately equivalent to a right heart catheter. But please keep in mind a right heart catheter and a CardioMEMS are two different devices giving two different pieces of information. You cannot just equate them on a one-to-one basis. The information that one derives is, if you like, additive and symbiotic, but it gives a good hint on where the pulmonary artery pressures are going and in which direction. So, all in all, a very good improvement. And as I was saying, it's around between 200 to around 450. To compare it to our right heart catheter, you can, you know, divide it by 85. Who is good at math. No, I won't do the test here. But it's around 3 to 5 mm of mercury. If you look at it, what has been published in the literature? A reduction of 3 to 5 mm of mercury. And this is not exactly the mean pulmonary artery pressure. This is a diastolic pressure, very similar though, you see, there is a marked reduction in mortality. Again, this does not mean that our patients had reduced mortality due to smaller trial size, but it is an indicator that improvement is heading in that direction, between 19% and 30%. If you reduce the pressure between 3 and 5 mm of mercury. Again, what is important is that all these three—Reveal risk score, functional class, and CardioMEMs data—are pointing in the right, or in the same direction, in this case, the right direction. So what I had said, I'd like to just repeat. 43% of the patients that were revealed risk score showed an improvement in function. Class one third showed an improvement. 86% either improved or were stable, and the CardioMEMS data again showed promising results with the measurements. With that, I'd like to briefly hand over to my dear colleague who is the head of preclinical development, Nick, please. Nick, thank you very much. Thank you very much.

Nicholas Oakes
55:58 - 66:13

Yes, it's a great pleasure to be here and share some of the results with you today in this wonderful building and this very nice city. So, I'm going to just show you some results. I'm going to take a little detour now and move into some preclinical results with a very closely related compound to CSO-1. This one's called CSO 14. And, you know, we've been sort of looking up until now at a bit of a cartoon world where we depict vessels as being very straight-sided structures, and they're highly simplified. The reality is, however, quite different. And if we look first at a healthy vessel, we observe it under a microscope. These are tiny vessels, less than one millimetre in diameter. What we see is the image to the left, and in the center, you'll see an oval-shaped object. And what you're looking at is a vessel that's been cut side-on, and it's the cross-section of that vessel. Surrounding it are the tiny air sacs that make up the lung. And now, on the right-hand side, what you see is a very different and very nasty picture of pulmonary artery hypertension. This is from an animal model, but a very similar picture emerges in human beings with PAH. And that central open lumen has been filled in by all of these proliferating cells here in the middle. And a single lumen has been replaced by multiple very tiny lumina. And this makes it extremely difficult for blood to flow through that vessel. Now, the reason, you know, we've been talking a lot about our hypothesis, but here's the reason that we believe that this principle, CS1, and this very closely related molecule, CS14, can do the job of remodeling these vessels. And it's shown, first of all, if we look on the far left of the figure that you see on the left hand side, there, you can see the occurrence of these kinds of plexiform lesions in the lung. They don't exist when you look in this animal model of pulmonary artery hypertension and don't treat them, you see the incidence is around 20%, meaning 20% of the vessels that you look at under the microscope are blocked and filled in with these plexiform lesions. And then, what we've done is treated the animals for just three weeks with different increasing doses of CSO 14. And we can see that we dose-dependently and gently reduce the occurrence of those vessels. So, um. Yeah. I'm sorry. So now if we switch back again to the clinical study, we can't actually image those vessels in that detail. So we're forced to use indirect methods to assess the degree to which the vasculature is blocked, and the parameter that best reflects that is the pulmonary vascular resistance, or PVR. And you know, what you see on the left-hand side of this slide are the pretreatment levels. So as Rahul pointed out, we measure with this methodology at the beginning and at the end. So at the beginning of the trial is plotted on the x-axis and at the end of the trial is plotted on the right axis, and if there was no effect at all, all of these points for all the individual patients in the study would lie along this diagonal line, and you see that some have fallen below the line and some are a little bit above. But overall, there's a general tendency for the entire group to fall below. And what I want to draw your attention to are the ones that are encompassed in this rectangle, which are really extraordinary. We saw marked reductions in PVR in five individuals. And if we look in the literature at reference information from large studies, placebo-controlled trials. These subjects were on standard of care treatment. We would say that having reductions of this magnitude is very, very unlikely. So we were really interested in understanding more about those individuals who had these very large reductions in PVR. Consistent with our hypothesis. And so when we examined the data further, what we could see was that the figure on the left-hand side illustrates the relationship between the change in pulmonary vascular resistance on the x-axis and the change in stroke volume. So, how much blood the heart pumps in a single stroke, in a single beat from the right side of the heart. And what we could see is that in those individuals, shown in purple, who had very large reductions in pulmonary vascular resistance, we observed that they also demonstrated a very large increase in stroke volume. So we had evidence then of our main hypothesis reversing the vascular remodeling and also an improvement in right ventricular function. Now. So we have evidence that we've fixed the plumbing in this group of patients. But what about their clinical status? Well, this slide really shows, I think in a nice way, how we have not only fixed the plumbing but also the prognosis of the patients. So in those individuals where we saw these very large reductions in PVR and the increases in stroke volume. We also see that they have improvements in reveal risk score and also functional class, which gives. This really gives a sort of central verification, if you like, of our hypothesis. So just bringing together then the clinical and preclinical data, and as Rahul mentioned at the beginning here, we don't see any clear dose dependence of efficacy in our trial. But you know, we have to acknowledge we have a small trial, but we think we understand why that is. And the reason we think that we don't see any dose dependency is that we are already at supratherapeutic levels of drug. And that's shown here in this slide, in this figure to the left, where we compare the exposures of the drug from the preclinical work with the exposures we achieved in the clinical study. And you can see that all of the doses, even the low dose, are above the levels of maximum efficacy that we saw in the preclinical studies. So we think that this indicates that we are already at a very good level of exposure at the lowest dose. Um, so yeah, if I take this one just to summarize, then, I've shown you some data, preclinical data demonstrating this very beautiful and robust reversal of the remodeling. This is what we're really talking about. Um, also specifically, this hallmark feature of pulmonary artery hypertension, which includes these plexiform lesions. I forgot to mention that we see in those studies a reduction of fibrosis and that the maximum efficacy is occurring at equivalent exposures to the CS1 trial, already at the low dose, which is why we don't see this dose dependency in that study, and that 24% of the patients responded with these remarkably large reductions in PVR and associated improvements in prognosis; these were very substantial reductions, and these changes in hemodynamics are consistent with our hypothesis that we are improving clinical outcomes. So with that, I hand back to you, Rahul. Thank you very much.

Dr. Rahul Agrawal
66:13 - 67:49

Thank you. So the remarkable thing is, as Nick was mentioning, the reversal of plexiform lesions, even in the preclinical models, something very unique. And this is something we're really excited about seeing. I mean, we're also excited, of course, about the results, but also about the explanations. And we're seeing this in the preclinical phase. We have shared with you the results. We have shared with you preclinical data that we're excited about. But we thought it would be equally interesting, and perhaps even more so for you, to hear from an investigator about his observations of the patients. He treated several of the patients in our CS1 trial, and maybe I could request Julia to ensure that the doctor is now tuned in, and I'll just briefly introduce him. Doctor. Doctor Gutiérrez is a professor at the University of South Carolina. He's a principal investigator. He's the chief of the Heart Failure Clinic in South Carolina, belonging to Prisma Health, which is a $7 billion hospital chain, the largest in South Carolina, with several thousand beds. So he sees a lot of patients. And we had requested Doctor Garcia to share his thoughts on what excited him to join the trial. But what he saw while treating several patients with CS1 and what his impressions were. So, Jason, I hope you can hear us and thank you so much for joining.

Dr.Jason Guichard
67:50 - 67:55

Yeah. No problem. Thank you all. Um, so thank everyone for coming. Can you hear me? Okay.

Dr. Rahul Agrawal
67:55 - 67:56

Very nice. Yes.

Dr.Jason Guichard
67:56 - 71:04

Okay. Perfect. Um. So. Yes. Nice to meet everyone here. Virtually. And why? We decided to collaborate with Sereno on CS 1003 for three main reasons. Number one, a novel pathway in this rare disease, which you guys have already heard about this morning. So that's number one. Number two, being an oral medicine, I'm not sure if you've discussed the therapy for PDR, but it involves a variety of approaches, ranging from oral to IV treatments. Of course, as you might imagine, with any disease process, oral medication is always preferable and advantageous from a patient standpoint. Um, so CS1 is an oral medicine. And then number three was the CardioMEMS component of this trial. So, we have a very active Cardiomems program. So it was combining two things that we loved and Cardiomems. So this was a trial that we were very interested in. Our experience with the trial has been positive; the patients have done very well across the board. The patients experienced symptomatic benefits very early on. Even at that one-month mark, you know, from a couple of weeks to one month. I think one of the most important things of all is that the side effect profile was minimal. You touched on it earlier today. The side effect profile. The side effect profile of a lot of these medicines is very high, leading to many headaches. Lots of GI side effects, pain in some cases with some of the ways we administer the medicines. There were very few side effects from CS1. Very few patient complaints, which is actually quite unique in the pulmonary hypertension world. And the feedback we received, as I mentioned, indicated that the patients felt better. We were invited to participate in the expanded access program. The patients resoundingly wanted to participate. There wasn't a single patient that we had who wasn't interested in getting back on the medicine. In fact, a few of them always expressed a strong desire to return to the medication because they felt significantly worse without it. Anecdotally, I've seen the evidence from the trial already. But anecdotally, we had a patient who came off the medicine after that last red heart cath, when the trial was finished and began to kind of backslide a little bit in the months after getting out of the hospital or after the trial completion. We repeated his heart catheterization to see if he needed additional medicines, and his hemodynamic numbers had returned to their previous, poor levels. Right back to where they were before the medicine. So he definitely had a regression in his disease process coming off the medicine. And we had to get him started on additional therapies to help improve those numbers. Um, so lots of positive experiences, both from the physician side and from the patient side for this medicine. That's novel. That's oral. And, of course, we had positive results with CardioMEMS. We're very excited for CS 1004, and as well as utilizing Fluida. I think this would be a very interesting and fascinating way of looking at the disease process and reversibility. Um, and I'll go ahead and pause there and see if anyone has any questions.

Dr. Rahul Agrawal
71:04 - 71:45

Thank you so much for sharing your thoughts and input. Are there any questions you might have for him directly since he has experience with patients? He has included nine patients in our trial. So any questions for Doctor Gushue. This is a one-time opportunity where you can ask one-on-one, unfiltered questions to one of our most active investigators. Yeah. Where? Oh, sorry. Yes, please. Microphone here, please. If you could just kindly say your name for him.

Joe Hedden
71:45 - 72:18

Hi, Joe Securities. Um, just wondering if you could perhaps give a little color on when you're talking about improvements that you see in terms of patients walking into the clinic, like how stark has this been in perhaps some of the most positive cases? I mean, how can you lay that out for us visually? Not the hemodynamics, etc. , but in terms of how they appear and what they're able to do. Like, is that obvious? Yeah.

Dr.Jason Guichard
72:18 - 73:50

Good question. Um, and yes, it's obvious to the patients and it's obvious to us. So probably the biggest improvement is in daily activities, right? So they are able to dress themselves a little bit easier. You know, vacuuming their house becomes a little bit easier. Um, you know, playing with their kids or grandkids becomes a little bit easier. It's essentially your daily activities or activities of daily living where that improvement really becomes evident. Um, as far as the degree, I think that was kind of another one of your questions. The pH when you first get diagnosed, you know, is kind of the standard of care at least on the front end for most patients, which is what we call combination therapy. So, a PDE5 inhibitor or NO pathway as well as an ERA. Generally speaking, when you get patients started on that combination therapy upfront, patients will feel better and have that incremental symptomatic benefit with the patients who started on CS1. You know, I would say that that same benefit, um, was again, kind of twofold, right. So patients, you know, get better with that first step of medicines. Um, and then when they got started on CS1, you know, that same kind of incremental additive benefit, um, you know, after those two medicines. You can definitely see improvement in a relatively short period of time when starting additional medication, which is exciting to observe. And of course, we didn't know at the time, you know, the results of the study or the hemodynamics behind the scenes. You know, we just kind of saw the patients. But to see that the hemodynamics internally improved as well as externally seeing those symptom improvements. You know, just an exciting win for the medicine.

Joe Hedden
73:51 - 74:20

And perhaps just another one on the patients who have a really remarkable PVR response. Um, and I'm not sure how many of those patients were yours or whether you've seen data from all the other centers, too. But is there any kind of commonality that's strikingly obvious from those patients? And perhaps, you know, any insight into how you might enrich future trials? Or is it too early to say at this stage?

Dr.Jason Guichard
74:21 - 76:02

Yeah. So that's a good question. And I don't have the individual patient data. Um, you know, matching up which ones, you know, the PVR, you know, matched up to their symptoms or which patients they were. Um, however, I will say, you know, the PVR is a great measure of improvement that combines two important measures, right? Your PA pressures as well as your cardiac output. So, it's a very good surrogate for several positive outcomes, if you will. And we do see that as the PVR comes down. You know, the patients do feel better. Um, but specifically, which patients had the best benefit. And if we were taking care of them, I don't know that. Um, but I will say that, you know, those are all very exciting outcomes for this medicine. And, you know, every patient's going to be a little bit different. And patient selection is going to be tricky. You know, as Doctor Benza would say, or, you know, would attest, some patients do very well on these medicines and some patients don't. And just like with any disease process, whether it's high blood pressure or high lipids or what have you, in cardiology, you're going to have your non-responders, your average responders, and your super responders. Um, and it's the same thing with the pH world. Sometimes, people can have life-threatening high pressures, and you just start them on one or two medicines and it completely gets better, whereas some people need three or four. Um, so there's, you know, the human body is way more complex than just kind of a simple pressure. Um, and sometimes it takes, you know, one medicine or more to manage these patients. And it's, you know, if we ever figure out which patients are going to respond and when, you know, that'll be kind of the holy grail in all of medicine, not just pulmonary hypertension, but definitely something that I'm sure people are working on.

Joe Hedden
76:04 - 76:05

Great. Thank you very much.

Dr. Rahul Agrawal
76:06 - 76:17

Okay. Thank you so much for taking time out of your busy schedule. And I know it's early morning where you are, but thanks a lot for sharing your thoughts.

Dr.Jason Guichard
76:17 - 76:19

No problem. Happy to do it. Thank you.

Dr. Rahul Agrawal
76:19 - 81:41

Thank you. Take care. Bye bye. Bye bye. So that was, I think, very interesting to hear from him, who has observed several patients and shared his impressions. Allow me to continue. Um, briefly. We have heard from Jason. And now it's my turn again. I hope you're not getting too bored with me, but let us continue. Maybe the path forward. And that is something exciting. This is based on our experiences, our thoughts, and where we want to go. And we think we have an exciting plan to really create value, create a difference for patients, and really make a difference. Also, in this whole arena about which you had just briefly heard from Doctor Gushue regarding the expanded access, he is of course very interested. We already have one patient in. I think we had shared that in a press release, and we are working to get the others in as well. Expanded access, if you ask why it is taking so long? We are working on the paperwork, and paperwork is unfortunately something that takes longer and longer. So, we are working and we're going to get the patients in. There are many patients who are interested, as you also heard from Doctor Gushue. Many of his patients are interested in participating in that. I'll also briefly touch on the analysis of the trial. The analysis of the trial is ongoing, and of course, we'll share it with you. But right now we're still awaiting the tables, listings, and figures. And all of this will be coming over the next few weeks. We'll be publishing it over the next few weeks and months. And as it comes, we'll be, of course, sharing those things with you. Regulatory path. I'll just go briefly into that as well. And the fluid story. And for that, we also have a guest. But I'll go into that in more detail, albeit briefly. You heard from Doctor Benza this morning, didn't you? Yes. There are many benefits for CS1 that are evident. And that's why the compassionate use was actually instigated by an investigator who wanted to continue after the 12 weeks. So we, of course, applied for it. We received the designation allowing its use, which is also a good sign that the FDA is confident in the safety of this drug for patient use. So the first patient, as you know, was dosed in August of this year. And we're, of course, continuing our efforts to include more and more patients. So the expanded access or compassionate use is ongoing here and the activities are ongoing. As I was saying regarding the analysis, I'll just talk about that. They are, as we speak, being done and completed. And as they come in over the next few weeks and as we publish them, of course, we'll then share them with you as well. We are going to engage with the regulatory bodies. Absolutely. We're going to go through the FDA. We're going to go through the EMA. We're going to present the data. But we will also talk about a Phase 2B trial. And if they want a Phase 2B3 trial, we clearly have a path forward in our minds. Naturally, the FDA has to approve it and so does the EMA. But we think based on the data we have, and the experience we have inside the company, as well as with our clinical steering committee, we have a clear path forward on how we want to progress, to gather harder evidence that CS1 is really making a difference in this patient group. And what I would further like to briefly share with you is the Fluida partnership, explaining what this is all about and what it actually entails. And here's what it is: it's a new method, and we'll just hear from the CEO of Fluida who will dial in any second, where you can show and visualize through CT tomography, computer tomography. You can visualize the vessels, as well as various aspects of the alveoli, in a color-coded fashion. So it's very visible. It's not invasive, of course. And you know that Nick was sharing about the plexiform lesions, but that can only be done with a biopsy. That's pretty dangerous in these patients. So we were looking for innovative methods that could really illustrate and demonstrate it. And we have found this method with Fluida that can show it. So, let us try maybe now to have the CEO of Fluida in here. And that is Jan de Buc. He has a very interesting background. We got to know him some months back at a conference. Jan is actually an aeronautical engineer. But then he, and you can maybe share that briefly, how you pivoted into this very exciting model of Fluida. So Jan, welcome and thank you very much for taking your time.

Jan De Backer
81:42 - 81:45

Thank you. Raul. Um, do you hear me? Well. Yes.

Dr. Rahul Agrawal
81:45 - 81:46

Yes, very clearly.

Jan De Backer
81:46 - 91:13

Perfect. Excellent. No, it's great to be here. And it's great to give you a little bit of a flavor of what functional respiratory imaging is. And since you mentioned the background, I'll very briefly mention that. So indeed, I'm an aerospace engineer by training. I went to Delft University of Technology. So not too far from, I think, where you are. My father is a respiratory physician, and he's a professor of respiratory medicine in Antwerp, Belgium. About 20 years ago, he commented, 'Oh, it's kind of cool.' You can simulate flows because I was using computers to simulate flows around wings, engines, and so on. Can you also simulate the flow in the lungs? And the reason he was asking that, at that time he was a reviewer for the EMA, and he said it's very difficult using just the conventional endpoints to really understand what these interventions are doing across various lung diseases, whether it was COPD, asthma, ILD, or pulmonary hypertension. So the idea was to see if we could combine methods from aerospace engineering with medical imaging to do two things: enhance our understanding of lung diseases in general, but maybe even more importantly, understand the effect of interventions. So, what do these drugs do in terms of changing airways or blood vessels, etc.? ? And can we maybe use it to speed up drug development? To the point earlier, can we possibly redefine some diseases around responder phenotypes to ensure that these drugs are as effective as possible? So, functional respiratory imaging, as you see here on the slide, is a relatively new technology. So it starts from the conventional CT scans. So we don't need to have additional hardware. We can work with virtually any site that has a fairly modern CT scanner. And maybe you know that today. Still, the vast majority of these CT scans are only visually assessed by a radiologist. And we believe that in that way, you probably extract maybe 5 to 10% of the information that's actually embedded in those CT scans. So, what functional respiratory imaging does is convert these 2D CT slices into 3D reconstructions of anatomical structures. So, we can look at airways, blood vessels, and lobe volumes in 3D. But we can also measure them and we can convert them into structured data. And in this day and age of artificial intelligence, structured data become quite important, becoming quite powerful through the use of inspiratory and expiratory CT scans. And these scans are very low dose. So there's not a lot of radiation involved. By taking an inspiratory and expiratory scan, we can make these static images come to life and we can look at regional ventilation area resistances, and we can also look at the deposition of inhaled particles. So just by using the CT scans, if somebody uses their inhaled drugs, we can see on a patient-specific basis where these particles end up. And are we sending the right drugs to the right parts of the lungs? So just by taking these two low-dose CT scans, you have a very comprehensive set of parameters that help us to understand what's going on in those lungs. So we have endpoints and structures that look at lungs and airways that we can visualize and quantify. We can look at the parenchymal structure including things like air trapping, emphysema, fibrosis as well. So it's being used in diseases such as IPF. Very importantly, especially for this compound, is looking at the blood vessel structures. And I'll show you a little bit more of that in a second. But we can look at the blood volume distribution. We can separate the arteries from the veins. So specifically for pulmonary arterial hypertension. Zooming in on the arteries is quite interesting. We can look at the blood vessel wall thickness and see how it compares with houses or within a diseased group and vessel tortuosity, or other parameters that we can specifically focus on. And then the last category is more the functional parameters, as I said before, ventilation, perfusion, etc. Because it's quite important, we believe, to see if we can get a good handle on the core function of the lung. And as you know, the core function of the lung is to make sure that the oxygen is transported from the environment into the bloodstream and things like ventilation, perfusion, etc. are obviously quite important for that. The visuals are also one element that is quite useful here. Instead of having to rely on somewhat black box parameters like symptoms or right heart catheterization, which essentially sum up everything that happens in the lungs. With these images, you can visualize on a regional level what's going on. And so here on the left-hand side, you typically see a healthy subject and then a matched subject. And these are the blood vessels. And so what you see immediately is that there's quite a significant reduction in these red zones. And the red zones are the smaller vessels. So you typically see that in pulmonary arterial hypertension, the small blood vessel volume reduces. And then the larger vessels dilate. So the blue zones here, which are the larger vessels, are significantly larger than in a healthy subject. So you do see a redistribution of the blood from the smaller blood vessels into the larger ones. You can visually see that and you can also quantify that. So here are some of the numbers where, compared to a healthy subject or a healthy group, you see a reduction in small blood vessel volumes. Here, the BPV five, which is the volume of the blood with a cross-sectional area below five millimeters squared. So that's kind of a technical term, the BV five. And then you see that blood is being pushed into the larger vessels; in this case, the BV ten, which is significantly larger than in a matched healthy control population. We see correlations between these parameters and hemodynamics. So typically if you look at the pressures, you see that if the pressure goes up, and the disease becomes more severe, you see a reduction in the small blood vessel volume and an increase in the larger blood vessel volume. We also see that when we compare it with the pulmonary vascular resistance. So higher resistances are associated with lower small blood volumes and larger large blood volumes. It's not just PAH where we can use this. We use it pretty much across all lung diseases. But indications like COPD, COPD, pH, as you see in this example here, are quite interesting indications because, in general lung diseases, the vasculature has been overlooked for many decades. We typically focus on spirometry, particularly in asthma and COPD sites, to see how the airways are affecting lung volumes. But we never really look at the vasculature because it's hard to do if you want to do it in a noninvasive way. But now, with these quantitative and functional imaging approaches, we can get much better insights there. And it opens up a whole pathway. As I said before, we can, especially using these advanced AI algorithms, separate the arteries from the veins. And that allows us to really focus in on these two sides, whether it's pre or post capillary, to get a better handle on what these drugs are doing, and potentially also look for phenotypes that respond quite favorably to some of these interventions. We can look at the blood vessel wall thickness. If we use contrast, we can measure the thickness of the blood vessel wall from the arterial and venous sides. So here in the pH subject, you see that the red colors indicate thickening of the wall compared to a healthy subject. And then the green colors on the venous side show that the venous side typically is more normal compared to or is matched with a healthy subject. So again, more quantification and visualization of these blood vessel wall characteristics. So we started the company almost 20 years ago. So we've been around for quite a while. And we see over those last two decades that imaging is really moving from, let's say, a nice-to-have more towards a need-to-have. So also because the standard of care is improving. Luckily for the patients, we see more and more drugs coming to market across all lung diseases. So there is a bigger need now to differentiate the various drugs or to look for better phenotypes in these patients. So we are working with quite a number of companies in the FX space and beyond that. And we were also quite experienced in training clinical sites. So we are also an imaging CRO. So we go to the sites, we train them, we make sure the image quality is optimal, such that the quality of the scans and the quality of the study can be optimized. So we trained more than 550 clinical sites worldwide. And we're very much looking forward to working with Serena to assess their new compounds and maybe several compounds in the future. Um, so if you have any questions, please feel free to ask. Here is my contact information if you want to know more; afterwards, send me an email or we can connect over LinkedIn. Happy to do that. So, please, if you have any questions, let me know.

Dr. Rahul Agrawal
91:13 - 92:23

Thank you very much for sharing those insights. Do we have any time for questions? Yeah. Okay. Any questions? As you can see, this is really top-notch. I used technology that can really visualize the vessels. Non-invasive methods. So this is what we are also aiming to use. As you heard from Jan and Doctor Gusha, we are going to engage at least one center for this and we're going to use this technology. We want to visualize. We want to show because we believe in CSS1 that it makes a difference in the patients' vessels, so that we are not merely theoretical; when we talk about this, we're not just theorizing, but actually demonstrating it. Nick demonstrated it beautifully in the preclinical scenario. We cannot biopsy patients for obvious reasons. But if we can show that here. Lovely. Any questions for Jan? Okay. We have one master question. Yes. Thank you.

Joe Hedden
92:24 - 93:01

Hello. Yeah. Joe Haden from Ark Security again. Um, so, on the previous slide, you showed some of the trials where you've been using this across PAs and other lung diseases. Just interested in what you observed? I mean, did you see some? Did you see some strong effects? In some of these trials, does that suggest any kind of disease-modifying activity, or are the effects just typical symptomatic responses? Are you able to tell the difference with the technology at this stage? Um, yeah. Just any color on that.

Jan De Backer
93:01 - 95:10

Yeah, absolutely. So a few of them already showed results like that. The Merck compounds, the MK 5475, is a vasodilator. Later. And there we conducted a study at different dosing levels. The drug works very well. So, it acts as a vasodilator, causing dilation of the vessels. Which was correlated with changes in the right heart catheterization data. Um, maybe interesting as well as the Gossamer data. So, the serotonin levels, um. The Tory study read out where we did see a significant improvement. Specifically in the BV5 to BV10 arterial ratio compared to placebo. So what we saw in that group is that the treated group increased in. Their BV5 volume. So the small blood vessel volume increased and the larger vessel volume decreased. So a redistribution of the blood vessels that we would think is associated with an improvement in these patients and that also correlated with stroke volume, improved physical exercise, etc. . So there's quite a lot of evidence that the CCT is a very sensitive endpoint to detect these changes, and the changes we observe tend to correlate with other clinical endpoints that indicate either stabilization, improvement, or deterioration in the placebo group. And so it's quite hopeful. And then we'll see a lot of data coming out, especially in addressing a very tricky disease, as you probably know, where there are a lot of things going on from the parenchymal side, airway side, but also from the vascular side. And there we also see quite interesting results. And those results will be released pretty soon. So yeah, as I said before, we've been doing this for quite a while. So it's not, let's say, a novel technology anymore. I think there's good evidence that this is quite a valid way of looking at lung function and structure. And we're looking forward to seeing more drugs coming through so that we can start to kind of see where all of these individual drugs can be positioned in the market.

Unknown 1
95:12 - 95:13

Thanks.

Dr. Rahul Agrawal
95:13 - 95:20

Okay. Thank you very much. One more. Okay. One more. One short question. And then. Yes.

Rebecca Smith
95:24 - 95:43

Rutger Smith. I wonder, can you see the difference between the blood vessels and the alveoli themselves? Can you follow the relaxation of the muscular tissue in the alveoli and so on?

Jan De Backer
95:44 - 96:28

So now, unfortunately, the resolution of the CT scan does not allow us to directly visualize the alveoli. So we can go to a resolution of about one millimeter. But the nice thing, of course, with fluid dynamics in general, is that everything is connected. So you kind of see if a signal happens more upstream, you can infer what's happening further downstream. So that's why looking at a redistribution of the blood volume from the larger vessels to the smaller vessels, or vice versa, is kind of a good surrogate to understand what's happening even more downstream in the microvasculature. So it's probably the most sensitive way in an in vivo setting to get to what is happening on a fairly small level in terms of the vasculature.

Dr. Rahul Agrawal
96:30 - 97:17

Okay. Thank you very much. Thanks a lot, Jan, for taking your time and sharing your thoughts. That was lovely. Thank you. I just got a signal right now. I mean, again, don't get me wrong, but if there are more questions, the pause will be shorter. Again, it's. But as you can see, we're working on several fronts to be innovative, to really elucidate as much as we can from CS1, gathering as much information as possible. And of course, a thing that patients can well tolerate, and hopefully, we move in the right direction fast enough to really create value for all of us, for patients, and for ourselves as well. Okay. With that, I'd like to briefly hand over to Stan. Thank you. Thank you very much. Good job.

Sten Sörensen
97:18 - 98:47

So now you have about. Well, it's seven minutes past. It's not five minutes past. So now you have eight minutes to take a break. I'm kidding. So about ten minutes. Come down here again. Bring coffee, tea, or water as a suggestion. And then we're going to look at CSO 14 IPF. It's going to be cool. And the countdown is done. So we're live again. It seems in the male audience, there aren't many men of the age with prostate issues. You made it back in ten minutes. Yeah. So anyway, joking aside, I hope you enjoyed the session about CS1, and now we have two sessions still left. So CS1 and CS014. So that's the analog of VPA, actually a very similar compound but with a better profile. Bjorn, the Chief Scientific Officer, joined the company when it was inaugurated in 2012. And actually, it's been part of developing another drug that's in development for IPF. So it has a long history, of course, and we don't have time to go through that. You don't have to. Please. The field is yours. Okay. Thank you. Can you hear me? Yes. Okay. Good. Good to see you. I recognized a lot of faces here.

Mike
98:47 - 114:06

Some of you must have been in contact with us before. So it's good to see you. And it's a pleasure for me to go into the details. You can call it a new indication, the CSO 14, going forward. And can I have the first slide, please. Oh, it's up to me to do it. Okay. Sorry. I've heard the first slide so many times. So this is CSO 14. You know it has been developed in relation to VPA to improve the molecule. It's a new chemical entity with patent protection. I will come back to more details about that. We are going to discuss the disease known as idiopathic pulmonary fibrosis. And that's a devastating disease. Patients suffer severely. They have a dry cough, almost constant, along with dyspnea and fatigue. The lung structure is destroyed with fibrosis, causing the lung to lose its compliance and its ability to exchange gases, with oxygen coming in and carbon dioxide going out. That is impaired. So these patients usually progress into respiratory failure. And the lifespan for these patients is in the range of 3 to 5 years. This disease typically occurs in middle-aged to elderly individuals. And I just made a comparison here with cancer diseases. And you can see that the survival for these patients is around a 45% five-year survival rate, which is below the average for cancer forms; it's severe and more severe than many cancer types. So this is really hitting the patient with both the survival and a very poor quality of life. And this is some more detail, just to show you that in the upper panel to the left, you see a normal lung with nice alveoli and vessels in between. In the lower panel on the left, you see the destroyed pulmonary parenchyma. Kima. So to say, not many alveoli are left, with lots of other tissues, and the blood vessels are far from the alveoli. So the fibrous tissue, if you go to the right here, you can see it kind of gets in between the bloodstream and where the air is coming into the alveoli, so that the condition progressively worsens. And it has been compared to constantly breathing through a straw. And try to do that sometime. You put a straw in your mouth. Breathe for a minute or so and then do something strenuous. It's really a poor quality of life. This disease primarily affects men. Some have smoked, so smoking has been discussed as a potential factor. But not every smoker gets it. It's still a rare disease. But it is idiopathic, so we don't really know what causes it. It's a form of scarring. It's misdirected scarring in the lung, you could say. So the progression of the disease is for many patients slow but constant. Some are rapid progressors, but the majority goes on a slope that ends in 3 to 5 years. But some have exacerbations, meaning that there is a significant drop in lung function, requiring hospitalization, which can be deadly. And we don't really know what happens when these exacerbations occur, but it's a very severe progression of the disease. There are quite a few patients in the world. If you take Europe and the US together, it's around 300,000 patients. But it's still considered a rare disease in both the US and the European area, fulfilling the criteria of being such. And you can have orphan drug designation for your drug. So it fulfills those criteria. The diagnosis you have heard about from John Debacker from Florida is that CT is a good measure. And you can see lots of things in the lung. Actually, high-resolution CT is something that you can also diagnose IPF with. In some cases, there are very particular and characteristic changes, and the diagnosis can be made using only CT; however, in some cases, you need to go further to differentiate it from other interstitial lung diseases. And then you perform either a biopsy from the bronchus, from the airways into the lung. Or you can do what I call BAL, which is you kind of inhale a liquid and then exhale the liquid and get some fragments from the lung. And you can do some histology on that. So that's the way you diagnose it. The therapy is very poor. You could say there are two available drugs and that's it. And there have not been any new developments for many, many years. The patients have several comorbidities. They develop pulmonary hypertension. There is an association between lung cancer and venous thromboembolism. And the therapy, if you examine it more closely, you can say that it modestly prolongs the life of the patients. There is a modest effect on progression, but the tolerability is very poor. Many patients don't want to take the medication, and many stop taking it because there is no promise of a cure. And what is really disturbing, I think, is that the therapy doesn't have any real good effect on symptoms either. So the patients have their cough, dyspnea, and other symptoms, and these don't have any real effect on mortality. So it's really a poor prognosis. So you can summarize that neither of the drugs is associated with any consistent improvement in patient-centered outcomes. Symptoms, physical capacity, or mortality. So that's really an unmet need to fulfill. So I said that there are several comorbidities which are important. IPF is associated with venous thromboembolism. And that's where we have kind of a stronghold with inhibition. It is associated with lung cancer where hijack inhibition has shown to have effects on some cancerous diseases. So I think we have a very strong position from that perspective. But also, you know, we have good data on pulmonary hypertension in the PA. These patients develop similar vascular remodeling to that of the PF patients. But it stems from a somewhat different aspect; it starts with IPF disease. And then they develop the remodeling successively. More than 50% develop pulmonary hypertension. And if they do that, they have a worse prognosis than if they don't. So that's also a very important aspect. So before I go into the rationale for why we believe CS1-14 is a good choice, it is because IPF is a devastating disease with poor quality of life and no cure. Survival rate is on par with the worst cancers. Therapy has poor tolerability. No effects on symptoms. You have a very modest effect on disease progression and no effect on mortality. So there is definitely a need for new therapy. Disease-modifying therapy. And then we come to HGF inhibition. And you have heard about it. You have seen this slide several times before. In 2019, I did a deep dive into the literature and found around 600 articles about Aztec inhibition in various diseases. Mainly, it was documentation for VPA and you have seen these effects. You can have a reverse remodeling of the vasculature. You can have an anti-fibrotic, anti-inflammatory effect. You can reduce pressure and achieve an antithrombotic effect. We think with this profile, an inhibitor could be very effective. Could be a very good match with the disease. Already in 2019, we developed this schematic where we attempted to identify various indications. And you can see there is a whole list. We have made progress. We proceeded with CS1 and now have IPF for CSO 14. So we are on that path. Does HGF inhibition fit with the disease? Yes. We don't have to go into detail, and we don't have time for that. But there are several publications showing that there are changes in the data just fitting Class One, which is the VPA and CSO 14. We had good data with Pi, with VPA, and there is a good association between Pi level and collagen formation in this kind of inflammatory lung injury. There is good data showing that IPF patients have about two times higher thromboembolic risk. And CSO 14, as said, has many properties similar to CS1. And it was developed to retain the benefits of VPA but improve on metabolism. So this is the patent-protected new chemical entity. It has very similar pharmacology and it requires essentially the same dosages. So it's a very good follow-up to the EPA. And there are several studies I don't have time to go into detail about that show that administering the EPA in models of IPF, primarily Bleomycin models, has an effect on the fibrosis that is relevant for this disease. And you have heard about the data on CSO 14, in the PF model showing both a reduced incidence of fibrosis but also a dose-dependent reduction of occlusion of lung arterioles and endothelial proliferation and plexiform lesions. And on top of that, Mike's work here in thrombosis is also relevant. We have three different models which have shown very clearly that CSO 14 is an antithrombotic without the risk of bleeding. So before I sum up, I just want to say that there is a close relation between pulmonary fibrosis, thrombosis, and pulmonary hypertension. So IPF patients have an increased risk of venous thromboembolism. Pulmonary hypertension affects up to 50% of the patients with IPF, and the pathogenic mechanisms are very similar. So what I've told you is that this is a devastating disease with a poor prognosis, limited therapeutic options, and a huge unmet need, of course. The rationale for using CS1 in IPF is that Jak inhibition, particularly VPA, has very good data on fibrosis, venous thromboembolism, and proliferation, similar to cancerous diseases. CSO 14 has shown in preclinical studies very good data on both fibrosis and vascular remodeling, and these patients often have pulmonary hypertension and VTE. So that said, I think we can see in the future a very important aspect of this disease being addressed with CSO 14. And I just want to finish off with this slide, which was a slide shown by John DeBacker, that we can look at the vasculature in a very profound way. I think we can also have a very good view of the fibrosis with this technique. So with that said, I think I'll stop there. Okay. So now it's my pleasure to introduce my colleague, STAT. And you are a professor at the University of Michigan. You were in clinical pharmacology, and you have a very keen interest in hematology, particularly in platelet function. So we are looking very much forward to hearing your view on CS 585 with these aspects in mind. Great. Please. Yes.

Dr. Rahul Agrawal
114:06 - 114:07

Well, thank you.

Unknown 2
114:07 - 131:11

And it's really a pleasure to be here to talk to you a little bit about CS 585 and the new preclinical program that we have, because it really takes us in a different direction. We have lots of patent protection on CS 585. I'm going to talk to you about where the holes and gaps are in current therapy, and where this will actually drive us forward in the future. So, those are platelets you're seeing. That's what happens when the platelets and the vessel see a site of injury. Since the 1980s, we've recognized that platelets are key in the blood for regulating thrombosis, and that every 34 seconds, someone dies of a cardiovascular disease, with 50% of those deaths due to clotting. And so the platelets play a key role. And that's why they're viewed as first in class. Right. The challenge is that we've actually focused on several targets. And we have developed many drugs targeting four specific receptors. And that's been beneficial. It's decreased morbidity and mortality by 26%. But still, as I mentioned, every 34 seconds, somebody dies of a cardiovascular disease. So we need to do better. But what we need are new targets, not new drugs for the same targets. And so the other challenge is that we need to decrease thrombotic risk. But we can't do that at the risk of bleeding. Bleeding can be more deleterious than the clot. So it's a tall task. But I think I can convince you here that we're onto something. Cyclic AMP in the platelet inhibits activation. There are some drugs on the market that attempt this. So, PDE3 inhibitors are used in very special cases but they're not well tolerated. So it's only under very specific circumstances that one can use them. We know that cyclic AMP is a viable target. The challenge is that targeting the activation and formation has not been successful to date. And we'll talk about where I think CS 585 has overcome some of these barriers. So we developed CS 585 to target the Prostacyclin receptor. I'll refer to it today as the IP receptor. We demonstrated that CS 585, potently in the low nanomolar range, can form cyclic AMP in the platelet, and that this formation results in the activation of molecular targets, in this case the activation of Vas phosphorylation. And you can see again at very low nanomolar concentrations, you achieve that molecular activation. That molecular activation translates into activation of the pathway and inhibition of platelets. We've shown, and this is all human data, that in human platelets we can inhibit the activation or aggregation of platelets through multiple pathways. I'm showing here collagen. But we've demonstrated thrombin and ADP. All the endogenous pathways to activate the platelet can be attenuated or inhibited through activation of the Prostacyclin receptor. Does this actually translate to the inhibition of a clot, which is a real issue in humans? So if we turn to animal models, we can see that CS 585 in the mouse potently inhibits injury-induced activation. We'll get into that a little bit later. And how that is different from the other Prostacyclin receptors that currently exist. So now that we have a pathway and we can validate its utility, there are a couple of questions that come up. There are other IP receptor agonists that exist. However, they are challenged. They're challenged with selectivity. They're challenged with having very short half-lives, and they're challenged with their utility in the blood. So this is why IP receptor agonists are limited in their clinical utility to pulmonary arterial hypertension and not to blood diseases themselves, such as thrombosis. So there are a couple of areas we wanted to determine. We wanted to determine. Is CS 585 able to be more selective than the other IP agonists that exist? And does it have sustainability? Can you administer it to a patient or an animal via the bloodstream? Does it have a long-lasting effect and is that effect reversible? So first I'm going to show you a little bit of data. And this is all human data. If we look at human platelets and we want to know if CS 585 shows selectivity. We can see that the molecular target I mentioned before, if added in a dose-dependent manner, causes activation or phosphorylation of that protein. If we inhibit different receptors on the platelet that go through similar pathways known to regulate cyclic AMP, such as the prostaglandin receptor pathways, the EP2 and the EP4. If we block those, you can see in the green line that it has no effect on the ability of CS 585 to phosphorylate Vasp. If we block DP1, the prostaglandin D pathway. It also has no effect. However, if we pharmacologically block the IP receptor prostaglandin receptor itself, we have no ability to phosphorylate or activate those proteins. So we can interpret that to easily mean that we are specifically going through that receptor. And what you see on the right is the dose dependency. And I want to point out that at the molecular level, we are inducing activation with as low as 100 picomolar of the drug, and with the IP receptor inhibitor, all of that is gone. We then ask how does that translate to actual platelet activation. That's why we repeated these dose-dependent experiments. And we looked at human platelet aggregation. And again, you can see blocking the EP2, the Ep4, the DP1. None of that affects the ability of CS 585 to inhibit platelet aggregation. Neither do they inhibit it. Or do they shift the curves? However, pharmacologically blocking the IP receptor completely reverses the ability of CS 585 to inhibit platelet aggregation, suggesting again selectivity towards that receptor. We now turn to whole blood. So, there's an assay we conduct in which we take whole human blood and float it. Arterial shear, what one would see in the carotid arteries. And we assess the ability of those platelets to adhere to a strip of collagen as they pass through. Collagen is what underlies the endothelium. So when there's an injury, it is the collagen that the platelets would see. And that's what causes the clot. And what you can see on the left in a vehicle control condition is that you get a lot of platelet adhesion to that collagen at arterial shear, which ends up being a thrombotic event. On the right, the same human blood treated with CS 585. You've severely attenuated the ability of those platelets to adhere under arterial shear. Now, if we look at the third row here, that represents CS 585 in still shots. But if you look at the bottom row, we've now taken that whole blood and we've inhibited the IP receptor. So if we inhibit the IP receptor, we completely reverse the ability to adhere to the underlying collagen and form clots. Again supporting the selectivity, and selectivity is really important because it is the cause of most of the off-target effects and nausea. The GI issues that we see with the IP receptor agonist currently in use. So we finally moved. That was all human data. We finally moved to animal trials to say, well, what in a very complex in vivo environment would happen with CS 585. And so we take anesthetized animals. We expose their arterioles, we take a laser to pinpoint cause, to pinpoint induction of a vascular insult. We use antibodies in the bloodstream to visualize the platelets as they enter and form a clot. Now, to know whether in this condition, which is as close as one can get to a human before you get an IND approval and can put something into a human, we use an animal that doesn't have an IP receptor. So this is again the in vivo experiment. And what you can see on the left is the real-time experiment as it's occurring. And you can see in wild-type animals on the top row you induce an injury. You get a clot within minutes, and the platelets accumulate. Wild type animal treated with a single administration of CS 585. You completely block that clot from forming. If we use an animal that lacks an IP receptor, you can observe an even larger clot formation when no drug is administered. But with CS 585, it has no effect on preventing that clot from forming. So each one of these assays was done repeatedly on 40 different vessels. So we have an N of 40 injuries for each condition. Highly reproducible. We then wanted to turn to sustainability. And we wanted to actually compare this to two drugs that are on the market. So we looked at Iloprost. First, we administered a single dose of Iloprost to the mouse and observed the effects at various time points. How long would we have protection? With Iloprost, you are fully protected for ten minutes. Well, that's not surprising, since the FDA guideline for Iloprost is to administer it 6 to 9 times a day, and it does not have, nor is it reported to have, any utility in the regulation of thrombosis. Then we turn to one of the newer drugs, selexipag. Selexipag is better. We can block platelet activation for up to four hours, but again post four hours you have full activation that occurs. And that is really in line with the half-life of Selexipag. We then compared that to CS 585. And what you can see with CS 585 is that through the entire IV 18-hour time window following a single administration, we have full inhibition of injury-induced vascular activation. We then wanted to know, because we really thought about this as an oral administration. We wanted to see, well, if we gave a single oral administration to the animal, do we get protection? And what we found is that we protect from injury for over 24 hours. But importantly, at 48 hours, we achieve a full reversal. So what we have is a molecule that has sustainability in the blood, works for over 24 hours, but is reversible. This is really important. Where could we use this? right? So I just mentioned at the very beginning that thrombosis is a major problem and that 50% of cardiovascular deaths are due to clotting. But one of the really important issues is that there are several rare thrombotic diseases for which there is no treatment or inadequate treatment. And so here are a couple of those. We have ITP, which is immune-mediated thrombocytopenia. It's a rare autoimmune disease where the immune system mistakes your platelets for foreign bodies and destroys them. We have HIT, heparin-induced thrombocytopenia and thrombosis, where patients who receive heparin for procedures then form an antibody complex. And those patients bleed and clot at the same time, with a mortality rate of about 25 to 30%. VITT (Vaccine-Induced Thrombocytopenia and Thrombosis). You're all familiar with that due to COVID-19. And we have APS, Antiphospholipid syndrome. So APS is when antiphospholipid antibodies form in the body, causing immune cells to undergo netosis. That's neutrophil extracellular traps, where the immune cells literally explode. They release all their DNA into the blood and form a net. And that net, combined with active platelets, forms a thrombotic thrombus. And that's now appreciated. Netosis through the immune cell and activation of the platelets are the two key aspects of occlusive thrombosis in the microvasculature. So where would CS 585 actually have the best utility? Well, with ITP it's complicated. Platelets are a key aspect of the disease. But there are a lot of challenges in the disease due to the acute nature of onset and resolution and the fact that we don't fully understand how ITP progresses. HIT (heparin-induced thrombocytopenia and thrombosis) is most prevalently seen with unfractionated heparin, but with the shift from unfractionated heparin to low molecular weight heparins, the incidence has decreased. And with the increased use of anticoagulants such as factor ten inhibitors, that population has continued to decrease. Vaccine-induced thrombosis and thrombocytopenia. That is, throughout history, we've seen that patients who get vaccines will sometimes clot. And we also know that during Covid-19, if you didn't get the mRNA vaccine, there was a high incidence of clotting. In fact, I believe it was 1 in 10,000 patients in the hospital during Covid-19 who had a clot related to the vaccine they received, and that was typically the AstraZeneca or the Johnson & Johnson. And so, that's going to be challenging going forward because now mRNA-produced vaccines are becoming more prevalent. Therefore, VITT is going to decrease in its prevalence in society. APS. So let's think about APS for a second. So the hallmark is a decrease in cyclic AMP. We know that our drug increases cyclic AMP. So you start to address that. It causes netosis, and that netosis is directly related to the decrease in cyclic AMP. That's known. So by increasing the cyclic AMP, we can begin to address that. Neutrophils have an IP receptor so we can target them. And the other aspect of APS is platelet activation. So the platelet activation and netosis result in microvascular thrombosis. The only treatments for APS currently are vitamin K antagonists and anticoagulants. They work in about 80% of the patients, but only in the large vessels. So large vessel arterial thrombosis can be blocked in 80% of cases, but in 1 in 5, the anticoagulants will have no effect, as they have zero ability to inhibit microvascular thrombosis. No ability to inhibit microvascular thrombosis, which is the major pathology of APS, whereby the microvasculature that feeds the organs of the body causes dysfunction and eventual multi-organ failure. So what are we? What are we demonstrating? Well, our drug that we've developed can increase cyclic AMP in the neutrophils, prevent netosis, and can also increase cyclic AMP in the platelets to prevent platelet activation. And those two together can prevent thrombotic events in the microvasculature and begin to address and treat these patients. So when we think about the patient, why would we need to treat APS versus any other patient? Well, here are some facts about these patients: 1 in 2000 people exhibit some form of APS. It is defined as a rare disease. It falls under the orphan drug designation both in the US and Europe. It is thought to be responsible for up to 1% of thrombosis worldwide. 20% of people younger than 50 who have a stroke are thought to have an APS as part of that cohort, and it's reported to be ten times more prevalent in women than in men. The unmet need. Well, the only treatment is the vitamin K antagonist, and the vitamin K antagonists don't work. They don't work where the real pathology is, which is the microvasculature that feeds the organs. So these patients are in an environment where they really have no alternatives or opportunities. And catastrophic APS results in microvascular blood clots leading to organ dysfunction and failure. CS 585 has significant potential. It's a novel therapeutic for limiting clotting based on the neutrophil and platelet's ability to target both, and, based on the characteristics of CS 585, it increases cyclic AMP. It's highly selective and has long-sustaining activity in the blood. This might be one potential target for CS 585. As we move forward with that, I thank you. And I'd like to invite Stan to come back.

Sten Sörensen
131:11 - 145:52

Thank you. Thank you. Mike. It's almost like you want to make an applause when you speak. Yes. So, you know, before I continue, you've heard from scientists and experts in the field here. And I think you get a feel for how we work at Suriano, right? So, deep science, medical need, and targets where we can deliver the most value for the patients. And so, you know, we're moving fast in our agenda. And I have a few minutes here to talk about strategic priorities and future outlook. And then we have, I think, 20 minutes depending on how I do to have questions and answers. I think also for those of you who have time to stay, that might be an even better session for Q&A because you can approach individually and talk with Mike, Nick, Rahul, or Bjorn. Okay, so the strategic focus of Serrano, and what about the future? Well, you've heard today about CS1 and the focus on rare disease as the initial target indication. We've got good safety and tolerance data in our Phase II. And it looks exciting that we can improve the risk score in 43-44% of the patients. That improvement represents a 23% reduction in mortality risk within 12 months. So that's what the physicians would like to do. What they also like to do, maybe even more, is to improve the function of these patients. The functional class, actually the physical capacity, is crucial because they're living quite short lives; they want to live as well as possible. So that's the functional class, the physical capacity. And of course, you want to address the hemodynamics and protect the heart. So, PVR increases stroke volume and stops the pathological remodeling occurring in both the vessels and the heart, preventing eventual heart failure. So that's our target. We're moving towards the final analysis and then into the next program to confirm what we have said and maybe more. And of course, with Fluida and the compassionate use program, that's going to be long-term therapy with CardioMEMS as a tool, with Fluida as a tool, and all other measurements. So our drug can also, in that compassionate use program, be titrated to the dose the physician likes to use. Of the three, we now have CSO 14. Today we communicated that we are moving that into a rare disease, also a deadly disease. Even shorter timelines than you heard from, regarding life expectancy. So the mean lifespan is around 3 to 5 years, similar to severe cancer. And that also attacks the lungs, if you will. But on the lung side, not the pulmonary artery side. And with the capacity, the characteristics, and the documentation that already exists. And there's information about DAX involved in this development. And we have documentation on VPA, the mother molecule if you will, that it actually works in IPF. So that's super exciting. We're conducting the clinical trial phase one now. So that's in healthy volunteers. That's going to be done by summer. And then we're going to move towards FDA or Europe. We'll see and pursue an IPF study. Right. In phase two. So that's not too far from now. And of course, now you just heard about CS 585. And you heard right. We're looking at rare diseases also for that compound. We haven't selected it. But you saw Mike's recommendation; here in his analysis, it seems apps look really good, right? So we'll see where, when, and what indication we'll pick. It might be apps. Now that program is ongoing under the leadership of Nick Nicholas Okes, our head of preclinical, who's been with Astra for ages. And we're thankful to have you with us. And that program, we hope will conclude by 2025 and then move into the clinic. So, that's our target. So that means toxicology studies. Et cetera. Etcetera. Next year. So, increased focus on rare diseases. Why? Well, we're working with patient need as the driver for us. We want to help patients, but, you know, our drug needs to fit those needs. And there are significant unmet medical needs in the indications we've talked about today. And our drug seems to have a high potential to deliver value. Our drugs, when introduced to patients with more severe diseases, have a greater impact if they are effective. That's better, right? You have high potential. Orphan drug status is attractive from a business perspective. There are incentives, of course, but you also get exclusivity. Also upon market introduction in Europe and the US, 7-10 years. And of course, it has a shorter development timeline and is less capital-intensive to develop. So, that's really a good fit for a biotech, right? So, a major common thrombotic indication is 10,000 to 25,000 patients to get it approved. So it's a big, big opportunity for big pharma. And these things we can pursue longer ourselves. Yeah. So, a quote. So, how does our portfolio look now? Well, if you look to the right here, IPF is certainly on our portfolio as a target. So, as I said upfront, we are developing this to be attractive for physicians and patients. But often, in 70%, 75%, maybe even 80% of cases, new drugs are developed by biotechs but are snapped up by biopharma before they go to market. And pharma excels in marketing. The last clinical trials were followed by focused marketing efforts. The doctors serve the patients. They do that best. But biotech actually is more innovative. Global biotech and pharma are significant sectors. So the more attractive the portfolio, the more likely that a biotech will do a good deal for the company and for the shareholders, and not least for drug development. So just a quick look, you know, at how do you build the biotech? Well, the company started in 2012; the vision was to prevent thrombosis through endogenic strengthening of the defense mechanism, via Hdac inhibition and epigenetic modulation. We moved into orphan disease focus in 2019 because our evaluation showed that the characteristics of Hdac inhibition were a superb fit with PF. Around that time in 2019, we also made key decisions. And I've had communication with some of you about this. Oh, there's something new coming. Well, we started several years ago, but you didn't know. So strategic focus is always way ahead of the communication to the market when it comes to. The details of the secrets that we are pursuing. But we decided to broaden the portfolio. So we acquired. CSO 14 came from a group at Astra, a biotech group that had been associated with Astra previously. But we also made a deal eventually with the University of Michigan after working for some time with Mike. And it's actually Mike's innovation. He's the innovator behind CC 85, and all that work was published recently in Blood, the most prestigious journal in the field of blood diseases. We also decided several years back to pursue a new chemical entity strategy. The first program is a repurposed compound that has been on the market for 60 years for epilepsy prevention. But if you want to build a company, you could focus on repurposing. But we thought, and we think that Hdac inhibition deserves more molecules, and we have improved VPA into CSO 14. And we're pursuing that now for IPF. So all those strategies were decided from 2019 to 2023, and we acted on them. And so now, in 2024, we reflect on what has happened. We have multiple clinical assets. We have two in the clinic now, one in phase one. One just completed the first phase of phase two. And we have increased our orphan disease focus. That's happening now and may not be a strategic move, but we have completed the phase two trial and that has provided some very valuable information. As this progresses, we become more strategically appealing to pharmaceutical companies. But what has also happened, and you're part of this, is that we have grown in the number of shareholders who are investing in the company, and that's very good for us and for the vision and mission we have. So you can look at this in different ways. And I've shown an earlier slide of this before. But when you go from a generic compound in an idea, you don't have a lot of value. You can't do a business based on that. But if you pursue a target where it has value and a benefit, and formulate that into a strategic plan, you can increase your value. And as you then build the company and develop more assets, your new chemical entity, and transition into the clinic and then into the rare disease space, the value of the company increases, the risk decreases, and the interest from partners grows. And now in 2025, there are new things that will happen. So what will happen? We will pursue discussions with the regulatory authorities for the next program. It can be a B2B. It can be an A2B3 trial, a pivotal trial; we'll see. But we expect to get that done, and we have received approval for it. It's probably going to involve both the FDA and Europe due to the size of the trial. CSO 14 completion of phase one, moving toward the regulatory process to get phase two approved. I didn't write it there because I don't know the exact timeline. It might happen next year already. So, and then of course, long-term extended expanded access program and usage of CS1 in patients with CardioMEMS and the fluid technology that you heard DeBacker speak about. And of course, then in 2026, that's going to be a really exciting year. We're going to start the pivotal trial, perhaps, and also initiate phase two for CSO 14 and IPF. And we're going to start phase one. So we're going to have three drugs in the clinic in a little more than a year from now. Yeah. So, back to the patient. What if this could be a remarkable patient case, right. 50 years. Four years left to live. What can you do? What if you can do disease modification and help this patient? We achieved success with a remarkable patient case. As long as she could use the therapy. She was on triple therapy. We added our drug as a physician to her treatment regimen. Within three months, she moved to functional class one from functional class two, barely feeling her disease. So maybe we can offer this to many patients. And you saw from our trial that 25% of the patients are super responders, 44%. We decrease the risk by one point and improve the prognosis. Disease modifying therapy with CS1 inhibition now even shortens lifespan if you're unlucky enough to get IPF, since the current drugs don't offer disease modification. We know that this works in animals for this disease and that an attack is one of the involved drivers. What if we can provide CSO 14 to these patients with a disease-modifying drug for fibrosis development and prevent that CS 585. This is the most common cause of death, thrombosis. The drugs cause bleeding and are difficult to use. You can't add them together. What if you can add a drug here that doesn't cause bleeding? And especially, you heard today about rare diseases. And potentially, we can introduce that drug into a rare disease. Apps might be it. So that's what we are about at Serrano. That's what your money is going toward. Those of you who invest, so good. All good. So thank you for listening today and I'm now opening up for questions. Maybe I need some help here. I don't know if I need help, Julia. So, who has questions? I know Raul actually should. Am I moving here? You go ahead. You're supposed to do this. Not that I know.

Dr. Rahul Agrawal
145:54 - 146:40

All right. Perfect. So I'm surrounded now by green tables. Don't be in any way intimidated. But I think this was very exciting. This was, of course, my first capital markets day with Serena. But you heard about portfolio strategy, commercial innovations, and new ideas, as well as scientific innovations on all three compounds: CSO 1, CSO 14, and CS 585. So maybe there are some questions that you have. I would just like to warn you, there are already many questions coming from our guests who are on the internet, so please feel free to ask questions. And yes, the person is already here, please. And just kindly mention your name and then. Thank you.

Rebecca Smith
146:40 - 146:47

I'm Rebecca Smith. I have two questions. I'll take one at a time. First of all, I have a problem.

Unknown 1
146:48 - 146:48

Um.

Rebecca Smith
146:49 - 147:15

Accepting that already in 12 weeks, you have a remodeling of the arterials in the lungs. Have you shown that in animal models that this has already occurred? I would readily accept no new fibrosis, but rather a reversal. No.

Nicholas Oakes
147:15 - 148:52

Sorry. The point is, I think, absolutely spot on. It's a very short time period to say this. However, we know that in animal models we can achieve the effects that I showed in just three weeks. We don't know what the relationship is in terms of the duration between the effects in animal models and in human beings. But remember that we're talking about a three-month treatment. So, you know, I mean, we do believe that those effects are, you know, we compare the pretreatment situation with the end of the three months, and the data shows a remarkable change which would not be expected based on published data on patients, on standard of care; placebo-treated patients on standard of care would not show that magnitude of change. So yes, I think it is surprising that we see evidence that this is occurring. And all I can say is that, you know, if we extend the study for a longer period, we expect to see significantly more. You know, this is the data as it is. We compare the beginning with the end of three months. And these are the numbers that we see. And they are consistent with what we see. Preclinically.

Dr. Rahul Agrawal
148:52 - 149:19

And allow me to add, sorry, if I may just briefly mention, in oncology there are two VPA compounds, as you know. They have shown remarkable results already within three months. No, but it's a VPA derivative and they are showing they have not been biopsied but they show in oncology patients differences and already within three months. No, but it's a VPA derivative, and they are showing significant differences in oncology patients already within three months, even though they have not been biopsied. So that is maybe also a good indication.

Sten Sörensen
149:19 - 149:30

And maybe just to add, maybe you remember Björn, the studies with VPA, the animal studies that you actually showed up here. So what's the length of those?

Mike
149:30 - 149:36

Oh, it's about three weeks of treatment in those and quite dramatic.

Sten Sörensen
149:36 - 149:46

Impact on vascular wall thickness, etc. . And there's also data on cardiac hypertrophy.

Mike
149:46 - 150:00

So maybe we can talk about that. The ones we have seen in this short time are very responsive, and others take a longer time. So, I mean the time span could be different for different patients.

Dr. Rahul Agrawal
150:00 - 150:09

Also, allow me to just add, yes. Please have the next question. We'll have short questions, short answers. There are many more questions. Yes.

Rebecca Smith
150:09 - 150:37

My second question relates to the patent situation. If I were a clinician aware that valproate or valproic acid has been off patent for a long time, why would that be significant? How can you convince me? Sending my patient to buy a drug from Syria, or for probably thousands of dollars, rather than to any pharmacy for a few dollars?

Dr. Rahul Agrawal
150:39 - 151:55

That's a very good question. Would anyone like to jump in? Otherwise? I'll be very happy to. So number one, of course, we have a different formulation, as you know, immediate-delayed release. Number two, as you know also historically, there are many examples that demonstrate if you have uncertain dosages, there's no guarantee you can take a drug in a different combination or dosage and expect the same effect. I'll give you one example: sildenafil. Sildenafil Revatio. Also in PA, it is a drug that is approved and generates turnover of over $350 million annually with the 40mg dose; they offer 20mg, 40mg, and 80mg options. So it always depends, of course, on the approval. The FDA is very adamant about it. And so is the EMA. As you know, off-label. There's no control. But we know that once it's approved, physicians, hospitals, and especially specialized centers are very interested in only using the approved dosages. We are confident, and this is just one example. There are several other factors for which this would definitely make sense.

Sten Sörensen
151:56 - 151:58

In addition, it's illegal.

Dr. Rahul Agrawal
151:58 - 152:00

So that's a different thing.

Sten Sörensen
152:00 - 152:12

Yeah. I'm just saying that as a physician, you take a legal risk. So if something happens to your patient that you didn't expect. So that's a legal aspect. But thank you. All right.

Dr. Rahul Agrawal
152:13 - 152:19

Good questions. Questions. Further questions. Yes, please. There's a microphone coming. Yes, please.

Joe Hedden
152:19 - 152:48

Hi Joe, Head of Security. Just two on CS 014. Um, now that you've announced the shift to IPF for the development focus, can you just give us some commentary on commercial expectations and how that might have changed? And in the second one of the phase one trial, were there any biomarkers included that might be useful to kind of give an early, not efficacy indication, but, you know, some kind of activity relevant to the new indication?

Nicholas Oakes
152:48 - 152:49

I can take the second one.

Dr. Rahul Agrawal
152:50 - 152:52

Yeah. I think Stan can take the commercial aspects.

Sten Sörensen
152:53 - 154:16

Uh, yeah. I mean, the market for IPF is smaller than the total thrombosis prevention market, but we hadn't selected a thrombosis indication yet for that. So that could very well have been an orphan thrombotic disease of similar magnitude to what we have here with IPF. So? So I think that from that perspective, the market is attractive. I don't have the number in my head at the moment, but the market is very attractive. And for us, due to the need for new disease modifying agents. And as you heard before, they're not really there. And in addition, as a rare disease, you have the ability to both be protected for 7 to 10 years. If you get orphan drug designation, we assume we would get it. And then you see, the pricing of rare disease drugs is favorable. And the reason for that is specifically in the US, the government health authorities encourage biotech and pharma to develop treatments for this disease. Otherwise, there will be no new development. So it's attractive for us. But they don't have the exact numbers with me now.

Dr. Rahul Agrawal
154:16 - 154:22

But there's huge market growth, as Stan was saying, with only two drugs. But the second part of the question. Yes.

Nicholas Oakes
154:22 - 155:13

So in relation to biomarkers for CSI 14. So of course, we were very keen to build biomarkers into that study. But we are also very aware that we would like to keep those biomarkers simple and robust. We've actually incorporated biomarkers based on our experience from Mike's team. So to look at thrombosis but also to look at bleeding risk as well. So, we are assessing thrombosis and bleeding risk. And in addition, I can't say exactly what it is at the moment, but we're also looking at a specific biomarker of Hdac inhibition in that study as well. So yes, we are.

Dr. Rahul Agrawal
155:13 - 155:38

And maybe, if I may, also request Bjorn to give an answer. And there are two other questions related to CSO 14, and maybe you can answer those at the same time as well. Will CSO 14 target all patients or only those with pulmonary hypertension and IPF? And the second question, which was asked, is what are the next steps for CSO 14. Would you like to elaborate on that? Okay.

Mike
155:38 - 156:39

I think that what I wanted to say regarding the first question, the one about biomarkers, is that for IPF, while it's beneficial to use biomarkers, there is a very well-established primary endpoint for these kinds of studies. That's the forced vital capacity which has been accepted by the authorities. And it's easy to follow. And it has a very high acceptance. And nowadays, there is also a possibility to measure that on a daily basis at home, so that will be even easier to follow, so to say, in these patients. Because if you look at the historical data, there is a trajectory for these patients which is on a population level, very well defined, showing how fast they progress in this. And I think that the second question, just remind me what it was? What are the next steps?

Dr. Rahul Agrawal
156:39 - 156:40

You know, there was.

Mike
156:40 - 156:41

One before that.

Dr. Rahul Agrawal
156:41 - 156:46

Oh, that was the first one then. Are we targeting all patients or only those with.

Mike
156:46 - 157:54

I definitely think we target all patients because the fibrotic component and the data supporting the anti-fibrotic effect are very strong. But what I think is also that we have, with HDAC inhibition, both prevention and reversal of vascular remodeling, and that fits very nicely with the development that comes successively with pH. pH in these patients, who you can hopefully prevent the remodeling going into pulmonary hypertension. So that's the idea. So with this. So definitely yes, all the patients are well. The next step in this kind of development is to do a phase two trial, but we cannot reveal the design of that, and we have nothing to say about the exact design. But it's definitely a well-defined study that you can do with this primary endpoint that is available.

Dr. Rahul Agrawal
157:54 - 157:58

Thank you for this very short answer. Yes. Very brief.

Nicholas Oakes
157:58 - 158:10

Clarification. So what I was referring to as biomarkers were in the phase one trial, which involved healthy volunteers, and what obviously Bjarne was referring to? Yeah.

Mike
158:10 - 158:12

For IPF. Yeah. But that’s okay.

Dr. Rahul Agrawal
158:13 - 158:23

So with this. I have two more questions on the page. So if. Yeah. Perfect. Please just briefly mention your name. Yes.

Karl Gustafsson
158:23 - 158:41

So, my name is Karl Gustafsson. And I have a question regarding the phase two trial; CS1 was delayed quite a few times. Is this something to be worried about for future studies?

Dr. Rahul Agrawal
158:43 - 159:29

Why don't you? Yes, I'll take that. So thank you so much for that question. Keep in mind that, of course, we are a small biotech. We experienced a learning curve. And what we will do, of course, now we are much better informed. We're much better prepared. The CS1 compound is also better known. So with a focused approach, we will definitely be much more streamlined. Here, we have a clear path forward, as I had shared with the regulatory pathways: FDA, EMA. We know how that goes. We have all been there several times. We approximately know how the studies should look. We will make sure that we have the right partners with the right expertise to go ahead and take the next steps.

Sten Sörensen
159:29 - 161:06

If I may add that too, thank you, Rahul. So, you know, this initiated post-Covid. If you've ever listened to a head of a hospital in the US, I've done so several times. They were crawling on their knees. They didn't have staff, doctors were leaving, and other staff members were departing during Covid, and they didn't return. But the patient numbers increased. So there, the regulatory or administrative process to get the study done, approved, or contracted, etc., was much more difficult post-Covid. Post-Covid, the process became much more difficult. And it's not only Sereno that has experienced that, so that process took a lot out of us. In addition, we had both Cardiomems implantation and PF centers, so there were essentially two areas where we had to undertake this cumbersome process. So, they actually had a contract and ethical approval process which suffered from the same, you know, understaffed scenario and took much longer than we anticipated in all the centers. So that was part of this delay. Of course, we have a learning curve. We are looking forward to a trial, potentially phase three, but we haven't defined the protocol yet. It's unlikely that the majority of patients will have CardioMEMS. It's very unlikely. Maybe a segment of those will have it, and you don't need it in all the patients. That procedure is too cumbersome to implement in a large number of patients. Okay.

Dr. Rahul Agrawal
161:06 - 161:17

Okay. So any further questions here in the room? Yes, please. Just a second. Christina. Yeah. Just kindly mention your name. Thank you so much.

Karl Gustafsson
161:17 - 162:24

Hello. My name is Marie Obrenovic, and I have. I have a question, perhaps directed to you, doctor. Sure. And maybe to you, Nick. I've written them down. So, the first thing I want to do is congratulate you on the promising data. And related to that, I have a question regarding the dosing strategy. So the top line data indicated that the patients in the low dose group responded particularly well, especially with significant reductions in PVR. So do you think this might be due to possible saturation at the highest dose? Um, and will you optimize the dosing strategy for the upcoming pivotal trial based on these findings? And then secondly, in the interim results, you sort of also presented data showing an early onset of AMP production as early as three weeks, and a sustained reduction two weeks after the actual study. Did these top line results confirm the early and prolonged effect? And we have additional data to support these findings related to top-line data.

Dr. Rahul Agrawal
162:24 - 162:32

Thank you. First of all, thank you for the good wishes; I will now address them exactly. You'll start with the dosages, if I may say, and then we can continue.

Nicholas Oakes
162:32 - 163:43

So it's a really good question on the doses. Right. So you know we started with equal numbers of patients in each of the dose groups. But by the end of the study, we ended up with almost double the number in the low dose group. So we don't actually think that we have a dose relationship there. We think that once you have, you know, that 480 on board, that's all you need. Moreover, I think what's really important to say is that, you know, we would like our patients to stay on the dose that we give. And we know that the mid and the higher doses had to be lowered a bit for patients, and once we adjusted them, these doses were well tolerated. So that's not a problem. But, of course, when you do this, you would like to have a dose that is effective and well-tolerated. And that's what, at least initially, we think we see here. But you know, it's not a huge amount of data. Yeah.

Dr. Rahul Agrawal
163:44 - 164:33

Yes. And maybe the second part you mentioned regarding hemodynamics; I'll start where Nick ended. That is, we're looking for signs. And these are 21 patients where we looked at efficacy. Some of them really showed nice results. Is that sort of generalizable? No. That's why we need to do a larger trial. That's what the plan is. And there, I think with much more confidence, we will also tell you this is the effect, this is how soon it's coming in. This is the characteristic. So now I think yes, we are very happy that we're seeing those signs. But it is of course mixed with a slight speculative aspect as well. Okay. Thank you so much. I hear.

Sten Sörensen
164:34 - 164:34

Maybe.

Dr. Rahul Agrawal
164:35 - 164:57

I have one more question here. I have one more question here. And then, if there are no questions in the room. It's not like an auction, but you can still ask questions. All right, then I have one more here. And that's directed at you, I suppose. Stan, are you having ongoing discussions with potential partners for licensing either CS1 or CSO 14?

Sten Sörensen
164:57 - 165:40

I'll give you a rhetorical answer. Define discussions. Alright. Now, of course, we are meeting with potential partners. That's ongoing. But, you know, you'll see somewhere if there's a deal that's happening, right. So. And before that, nobody was talking. So I think, you know, we are gaining traction, and, you know, pharma companies are contacting us, I would say. But that doesn't mean that the deal is imminent. It just means that the attention is increasing. And if a deal were imminent, I couldn't tell you. Right. So just keep your shares.

Dr. Rahul Agrawal
165:41 - 165:42

Buy more.

Sten Sörensen
165:42 - 165:50

I never give investment advice, by the way. You know, it's just a joke. All right. Thank you so much. I have some.

Dr. Rahul Agrawal
165:50 - 165:50

Closing remarks.

Sten Sörensen
165:51 - 165:53

Remarks. Closing remarks. I won't. Thank you very much.

Dr. Rahul Agrawal
165:53 - 165:54

Thank you very much for the questions.

Sten Sörensen
165:54 - 166:03

Thank you, everyone. So what should one say here at the very end? I don't think there's more to say, actually.

Dr. Rahul Agrawal
166:03 - 166:04

By the way, sorry.

Sten Sörensen
166:04 - 166:05

We'll just see what you can do.

Dr. Rahul Agrawal
166:06 - 166:07

There we go.

Sten Sörensen
166:07 - 166:52

Yeah. So I think I said it before. So I think this environment at this time gives us more opportunity to show you what we are about, who we work with, what's driving us, and how deep the science is. So, that's the foundation of any good biotech or pharma. This has been a great opportunity to work with you, and I'm very happy that you are here. And I think there are a few online too. So thank you very much. And, you know, meet you up at the coffee. You can ask more questions and more privately, perhaps. Okay. Thank you.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…